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Over	  the	  last	  five	  years,	  X-­‐ray	  structures	  of	  CXC	  chemokine	  receptor	  4	  (CXCR4)	  in	  
complex	   with	   three	   different	   ligands	   (the	   small-­‐molecule	   antagonist	   IT1t,	   the	  
polypeptide	  antagonist	  CVX15,	  and	  the	  viral	  chemokine	  antagonist	  vMIP-­‐II)	  have	  
been	  released.	  In	  addition	  to	  the	  inherent	  scientific	  value	  of	  these	  specific	  X-­‐ray	  
structures,	   they	   (i)	   provide	   a	   reliable	   structural	   foundation	   for	   studies	   of	   the	  
molecular	  interactions	  between	  CXCR4	  and	  its	  key	  peptide	  ligands	  (CXCL12	  and	  
HIV-­‐1	   gp120);	   and	   (ii)	   serve	   as	   valuable	   templates	   for	   further	   development	   of	  
small-­‐molecule	   CXCR4	   antagonists	  with	   therapeutic	   potential.	  We	   here	   review	  
recent	  computational	  studies	  of	  the	  molecular	  interactions	  between	  CXCR4	  and	  
its	  peptide	   ligands	  –	  based	  on	   the	  X-­‐ray	  structures	  of	  CXCR4	  –	  and	   the	  current	  
status	  of	  small-­‐molecule	  peptide	  and	  peptidomimetic	  CXCR4	  antagonists.	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DEFINED	  KEY	  TERMS	  [underlined	  in	  main	  text]	  
	  
1) Peptidomimetic:	   A	   peptidomimetic	   is	   defined	   by	   IUPAC	   as	   “a	   compound	  
containing	   non-­‐peptidic	   structural	   elements	   that	   is	   capable	   of	  mimicking	   or	  
antagonizing	  the	  biological	  action(s)	  of	  a	  natural	  parent	  peptide.”	  Further,	  “a	  
peptidomimetic	   does	   no	   longer	   have	   classical	   peptide	   characteristics	   such	   as	  
enzymatically	  scissile	  peptidic	  bonds”	  [1].	  
2) Isostere:	   In	   the	   context	   of	   this	   review,	   an	   isostere	   is	   defined	   as	   any	  
functional	   group	   or	   moiety	   that	   is	   included	   in	   a	   peptide	   sequence	   as	   a	  
replacement	  of	  an	  amide	  bond.	  
3) Scaffold:	  The	  term	  scaffold	  is	  used	  for	  rigid	  (normally	  cyclic)	  structures	  onto	  
which	  the	  functional	  groups	  of	  amino	  acid	  side	  chains	  can	  be	  introduced.	  
4) Structure-­‐based	  and	   ligand-­‐based	  design:	   In	  structure-­‐based	  design,	  the	  
3D	   structure	   of	   the	   target	   is	   known	   and	   guides	   the	   design	   of	   active	  
compounds.	   When	   the	   3D	   structure	   of	   the	   target	   is	   unknown,	   indirect	  
information	  has	  to	  be	  used	  in	  order	  to	  design/optimize	  compounds	  that	  bind	  
to	  the	  target.	  This	  information	  is	  normally	  obtained	  through	  SAR	  studies	  and	  
pharmacophore	   modeling,	   and	   the	   overall	   approach	   is	   known	   as	   ligand-­‐
based	  design.	  	  
5) 7TM	  receptors:	  As	  signalling	  via	  G	  proteins	  is	  a	  common	  feature	  for	  seven-­‐
transmembrane	   domain	   (7TM)	   receptors,	   they	   are	   often	   referred	   to	   as	   G	  
protein-­‐coupled	   receptors	   (GPCRs).	   However,	   as	   G	   protein-­‐independent	  
signalling	   pathways	   also	   exist,	   e.g.	   through	   β-­‐arrestin	   recruitment,	   “7TM	  
receptors”	   is	   today	   considered	   to	   be	   a	   more	   appropriate	   name	   for	   this	  
receptor	  superfamily.	  
6) Polypeptide:	  The	  term	  polypeptide	  is	  only	  loosely	  defined	  by	  IUPAC-­‐IUB	  as	  
a	   peptide	   with	   more	   than	   10-­‐20	   amino	   acids	   [2].	   As	   10	   amino	   acids	  
correspond	   to	   a	   molecular	   weight	   (MW)	   of	   approximately	   1000,	   we	   here	  
define	   polypeptides	   as	   having	   10-­‐50	   amino	   acids,	   which	   enables	  
differentiation	  between	  polypeptides	  (MW	  >	  1000	  Da)	  and	  small-­‐molecules	  
(MW	  <	  1000	  Da).	  
7) Small-­‐molecule:	   When	   referring	   to	   molecular	   size,	   the	   word	   “small”	   will	  
have	   different	   meanings	   in	   different	   scientific	   disciplines.	   In	   the	   field	   of	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medicinal	  chemistry,	  the	  term	  “small-­‐molecule”	  typically	  refers	  to	  an	  organic	  
compound	  with	  MW	  <	  1000	  Da.	  
8) Alanine	  scan:	  In	  order	  to	  establish	  the	  relative	  importance	  of	  the	  side	  chains	  
in	  a	  bioactive	  peptide,	   a	   series	  of	   analogs	  where	  each	   individual	   residue	   is	  
replaced	   by	   an	  Ala	   residue	   is	   synthesized	   and	   tested.	   This	   is	   known	   as	   an	  
“alanine-­‐scan”;	  Ala	  is	  used	  because	  it	  is	  non-­‐functionalized	  and	  has	  the	  same	  
conformational	  preferences	  as	  all	  non-­‐Gly/Pro	  residues.	  
9) Retro-­‐inverso	  peptides:	  In	  a	  retro-­‐inverso	  analog,	  the	  N-­‐to-­‐C	  direction	  and	  
stereochemistry	   of	   the	   parent	   peptide	   are	   simultaneously	   changed,	   which	  
has	  the	  potential	  of	  resulting	  in	  a	  peptide	  with	  overall	  similar	  topology	  with	  
respect	   to	   side	   chain	   orientation;	   see	   reference	   [3]	   for	   a	   review.	  However,	  
due	  to	  the	  reversed	  N-­‐to-­‐C	  direction,	  the	  positioning	  of	  the	  backbone	  amide	  
carbonyl	   (H-­‐bond	  acceptor)	  and	  NH	  (H-­‐bond	  donor)	  groups	   relative	   to	   the	  
side	   chains	   will	   obviously	   be	   different.	   Also,	   the	   energetically	   preferred	  
backbone	  conformations	  are	  unlikely	  to	  be	  identical.	  
10) Peptoid:	   A	   peptoid	   is	   defined	   by	   IUPAC	   as	   “a	   peptidomimetic	   that	   results	  
from	   the	   oligomeric	   assembly	   of	   N-­‐substituted	   glycines”	   [1].	   In	   a	   typical	  
peptoid	  peptidomimetic,	  the	  side	  chain	  of	  each	  residue	  in	  the	  parent	  peptide	  
is	  moved	  from	  Cα	  to	  the	  amide	  nitrogen,	  meaning	  that	  the	  N-­‐substituents	  of	  
the	  peptoid	  are	  the	  “side	  chains”.	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1. INTRODUCTION	  
	  
The	   important	   roles	   of	   endogenous	   peptides	   in	   processing	   (substrates)	   and	  
signaling	   (ligands)	   mean	   that	   both	   proteolytic	   enzymes	   and	   peptide-­‐binding	  
(peptidergic)	  receptors	  are	  attractive	  targets	  for	  peptidomimetic	  ligands.	  	  
	  
Ripka	  and	  Rich	  have	   classified	  peptidomimetics	   into	   three	  main	   types:	  peptide	  
backbone	   mimetics	   (type-­‐I),	   functional	   mimetics	   (type-­‐II),	   and	   topographical	  
mimetics	  (type-­‐III)	  [4].	  In	  type-­‐I	  mimetics,	  an	  amide	  bond	  of	  the	  parent	  peptide	  
is	   typically	  replaced	  with	  an	   isostere,	  e.g.	  a	   transition-­‐state	   isostere	  as	  seen	   for	  
the	  HIV	   protease	   inhibitors.	   Type-­‐II	  mimetics	   are	   structurally	   unrelated	   to	   the	  
parent	   peptide,	   and	   only	  mimic	   (or	   antagonize)	   its	   function,	   as	   exemplified	   by	  
the	  angiotensin-­‐II	   receptor	  antagonists.	  Type-­‐III	  mimetics	   contain	   the	  essential	  
functional	  groups	  of	  the	  parent	  peptide,	  with	  the	  3D	  organization	  (topography)	  
maintained	  by	  a	  non-­‐peptide	  template/scaffold	  instead	  of	  the	  peptide	  backbone.	  	  
	  
While	  rational	  design	  of	  many	  peptidomimetic	  protease	  inhibitors	  has	  benefited	  
from	   the	   availability	   of	   X-­‐ray	   structures	   of	   the	   enzyme	   targets	   (i.e.	   structure-­‐
based	  design),	  design	  of	  peptidomimetic	   ligands	   for	  peptidergic	  7TM	  receptors	  
has	   traditionally	   relied	   on	   ligand-­‐based	   approaches	   due	   to	   the	   problems	  
associated	  with	  structure	  determination	  of	  membrane-­‐bound	  targets.	  However,	  
this	   situation	   changed	   in	   2010,	   when	   the	   X-­‐ray	   structures	   of	   the	   chemokine	  
receptor	   CXCR4	   in	   complex	   with	   the	   polypeptide	   antagonist	   CVX15	   and	   the	  
small-­‐molecule	   antagonist	   IT1t	  were	   reported	   (ligand	   structures	   are	   shown	   in	  
Figure	  1)	  [5].	  This	  represented	  a	  milestone	  not	  only	  in	  the	  chemokine	  field,	  but	  
also	   in	   a	   wider	   sense,	   as	   these	   were	   the	   first	   experimental	   structures	   of	   a	  
peptidergic	  7TM	  receptor.	  Very	  recently,	  an	  X-­‐ray	  structure	  of	  CXCR4	  in	  complex	  
with	   the	   viral	   chemokine	   vMIP-­‐II	   was	   also	   published	   [6],	   providing	   further	  
structural	   insight	   into	   the	   molecular	   recognition	   of	   large	   chemokine	   ligands.	  
Importantly,	   these	   structures	   also	   provide	   a	   reliable	   structural	   foundation	   for	  
studies	   of	   the	   molecular	   interactions	   between	   CXCR4	   and	   other	   ligands	   of	  
interest,	  including	  small-­‐molecules	  with	  therapeutic	  potential.	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The	   main	   focus	   of	   the	   present	   review	   will	   be	   on	   (i)	   recent	   studies	   of	   the	  
molecular	  interactions	  between	  CXCR4	  and	  its	  key	  peptide	  ligands	  (CXCL12	  and	  
the	  HIV-­‐1	   surface	  protein	  gp120)	  based	  on	   the	  X-­‐ray	   structures	  of	  CXCR4;	   and	  
(ii)	   the	   current	   status	   of	   small-­‐molecule	   peptide	   and	   peptidomimetic	   CXCR4	  
antagonists.	  
	  
2. CXCR4:	  BIOLOGY	  AND	  PHARMACOLOGY	  
	  
According	   to	   the	   International	   Union	   of	   Basic	   and	   Clinical	   Pharmacology	  
(IUPHAR)	  around	  800	  human	  7TM	  receptors	  have	  been	  identified	  [7].	  About	  half	  
of	  these	  have	  sensory	  functions	  (olfaction,	  taste,	  light	  and	  pheromone	  signaling);	  
the	  remaining	  non-­‐sensory	  receptors	  (356	  in	  total)	  are	  activated	  by	  a	  variety	  of	  
ligands,	   including	   ions,	   amino	   acids,	   monoamines,	   peptides,	   lipids,	   and	  
glycopeptides.	   Presently,	   121	   receptors	   remain	   orphan,	   i.e.	   no	   endogenous	  
ligand	  has	  been	  identified.	  
	  
CXCR4	   belongs	   to	   the	   subfamily	   of	   chemokine	   receptors,	   which	   orchestrate	  
leukocyte	   migration	   during	   homeostasis	   as	   well	   as	   inflammation	   [8].	   CXCR4	  
(initially	  named	  both	  LESTR	  and	  fusin)	  was	  discovered	  based	  on	  its	  function	  as	  a	  
co-­‐receptor	   for	   HIV-­‐entry	   [9-­‐11],	   and	   the	   68-­‐residue	   chemokine	   CXCL12	  
(initially	   named	   SDF-­‐1)	   was	   subsequently	   identified	   as	   its	   endogenous	   ligand	  
[12].	  The	  monogamous	  relationship	  between	  CXCR4	  and	  CXCL12	  is	  atypical	   for	  
the	  otherwise	  promiscuous	  chemokine	  system,	  which	  consists	  of	  ~25	  receptors	  
and	  >50	   ligands	   [13].	   In	  contrast	   to	  most	  other	  chemokine	  receptors,	  CXCR4	   is	  
not	  only	  expressed	  on	  leukocytes,	  but	  also	  on	  many	  other	  differentiated	  and	  non-­‐
differentiated	   cell	   types	   outside	   the	   hematopoietic	   compartment,	   including	   the	  
brain	   and	   the	   cardiovascular	   system	   [14-­‐16].	   Consistent	   with	   this	   broad	  
expression	   pattern,	   targeted	   knock-­‐out	   of	   either	   CXCR4	   or	   CXCL12	   results	   in	  
lethality	  in	  utero	  [17].	  In	  fact,	  CXCR4	  is	  the	  only	  chemokine	  receptor	  essential	  for	  
life.	   Furthermore,	   CXCR4	   is	   expressed	   on	   many	   cancer	   cells,	   including	   breast	  
cancer,	   ovarian	   cancers,	   brain	   tumors	   and	   a	   variety	   of	   hematological	   cancers,	  
where	  it	  has	  been	  suggested	  to	  influence	  metastasis	  as	  well	  as	  tumor	  growth	  and	  
angiogenesis	  [18-­‐23].	  The	  tumor-­‐expression	  of	  CXCR4	  has	  been	  exploited	  from	  a	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molecular	   imaging	   perspective	   by	   labeling	   CXCR4	   ligands	   as	   PET	   radiotracers;	  
for	   recent	   reviews	   see	   references	   [24-­‐26].	   Moreover,	   the	   CXCR4:CXCL12	   axis	  
controls	   release	   of	   myeloid	   and	   lymphoid	   hematopoietic	   stem	   cells	   from	   the	  
bone	   marrow	   [27],	   and	   recent	   studies	   suggest	   that	   it	   may	   also	   play	   a	   role	   in	  
recruitment	   of	   skeletal	   muscle	   progenitor	   cells	   during	   myogenesis	   [28,	   29].	  
Within	   the	   immune	   system,	   CXCR4	   and	   CXCL12	   regulate	   the	   migration	   and	  
maturation	   of	   a	   variety	   of	   immune	   cells	   (T-­‐	   and	   B-­‐lymphocytes,	   monocytes,	  
macrophages,	   neutrophils	   and	   eosinophils)	   and	   are	   thereby	   essential	   for	  
immune	  surveillance	   [13].	  The	  broad	  expression	  of	  CXCR4:CXCL12	  within	  (and	  
outside)	   the	   immune	  system	   implies	   that	  novel	   functional	  properties	  of	  CXCR4	  
are	  still	   to	  be	  discovered.	  One	  such	  role	   is	   in	  autoimmunity,	  and	  several	  recent	  
reports	   suggest	   that	   CXCR4	   is	   a	   biomarker	   for	   autoimmunity	   in	   e.g.	   type	   1	  
diabetes	   [30],	   autoimmune	  myopathy	   [31],	   and	   systemic	   lupus	   erythematosus	  
[32,	  33].	  
	  
The	   multiple	   physiological	   and	   pathophysiological	   roles	   of	   CXCR4	   have	  
stimulated	  an	  intensive	  search	  for	  CXCR4	  antagonists.	  The	  first	  CXCR4	  antagonist	  
to	  be	  tested	  in	  the	  clinic	  was	  the	  N-­‐acetylated	  nona-­‐D-­‐arginine	  amide	  ALX40-­‐4C	  
(Figure	   1A).	   This	   polycationic	   peptide	  was	   initially	   designed	   as	   an	   inhibitor	   of	  
the	  HIV-­‐1	  Tat-­‐TAR	  interaction,	  but	  it	  was	  also	  shown	  to	  interfere	  with	  HIV	  entry	  
[34].	   Clinical	   investigations	   were	   initiated	   before	   the	   discovery	   of	   CCR5	   and	  
CXCR4	   as	   the	   co-­‐receptors	   of	   HIV,	   and	   it	   was	   later	   shown	   that	   ALX40-­‐4C	  
inhibited	  HIV	  infection	  by	  blocking	  viral	  interaction	  with	  CXCR4	  [35].	  ALX40-­‐4C	  
was	   found	   to	   be	   well	   tolerated;	   however,	   it	   did	   not	   result	   in	   a	   significant	  
reduction	   in	   viral	   load	   [36].	   In	   1992	   the	   polyphemusin	   II-­‐derived	   18-­‐mer	  
polypeptide	  T22	  (Figure	  1A)	  was	  reported	  to	  show	  anti-­‐HIV	  activity,	  apparently	  
through	  inhibition	  of	  virus-­‐cell	  fusion	  [37].	  Following	  the	  discovery	  of	  the	  role	  of	  
CXCR4	   in	   HIV-­‐1	   entry	   four	   years	   later	   [38],	   T22	   was	   soon	   shown	   to	   be	   an	  
antagonist	   for	   CXCR4	   [39].	   By	   the	   end	   of	   the	   decade,	   structure-­‐activity	  
relationship	   (SAR)	   and	   downsizing	   studies	   of	   T22	   had	   resulted	   in	   the	  
identification	   of	   the	   14-­‐mer	   antagonist	   T140	   (Figure	   1A)	   [40],	   which	   today	   is	  
considered	   as	   the	   “prototype”	   polypeptide	   CXCR4	   antagonist.	   At	   this	   point,	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analogs	   [41]	  and	   fragments/dimers	   [42]	  of	  CXCL12	  had	  also	  been	  shown	  to	  be	  
CXCR4	  antagonists.	  	  
	  
	  
Figure	  1.	  (A)	  Sequences/structures	  of	  selected	  polypeptide	  CXCR4	  antagonists,	  and	  (B)	  
structures	  of	  selected	  small-­‐molecule	  CXCR4	  antagonists	  (functional	  mimetics).	  
	  
The	  first	  small-­‐molecule	  (MW	  <	  1000	  Da)	  non-­‐peptide	  CXCR4	  antagonists	  were	  
also	  developed	  during	  the	  1990s,	   including	  the	  bicyclam	  AMD3100	  (Figure	  1B)	  
[43].	   These	   compounds	   have	   no	   structural	   resemblance	   with	   known	   peptide	  
ligands	   and	   can	   be	   considered	   as	   functional	   (type-­‐II)	   mimetics.	   In	   2008,	  
AMD3100	   (plerixafor,	   Mozobil)	   became	   the	   first,	   and	   still	   the	   only,	   marketed	  
CXCR4	  antagonist.	  It	  is	  currently	  approved	  for	  stem	  cell	  mobilization	  in	  patients	  
A. Polypeptide CXCR4 antagonists
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with	  non-­‐Hodgkin's	  lymphoma	  and	  multiple	  myeloma,	  but	  clinical	  trials	  for	  other	  
indications	  are	  ongoing	  [44].	  Other	  small-­‐molecule	  functional	  mimetics	  that	  have	  
been	   tested	   clinically	   include	   AMD11070/AMD070	   (Genzyme),	   MSX-­‐122	  
(Metastatix),	  and	  TG-­‐0054	  (TaiGen)	   (Figure	  1B).	  The	  different	  classes	  of	   small-­‐
molecule	  CXCR4	  antagonists	  have	  been	  extensively	  reviewed	  by	  Neamati	  and	  co-­‐
workers	   [45,	   46].	   Similarly,	   several	   polypeptide	   CXCR4	   antagonists	   have	  
undergone	   clinical	   testing,	   including	   BL-­‐8040/BKT140	   (BioLineRx,	   Biokine),	  
POL6326	   (Polyphor),	   and	   LY2510924	   (Lilly)	   (Figure	   1A).	   The	   polypeptide	  
(polyphemusin	   II-­‐	   and	  CXCL12-­‐derived)	  CXCR4	  antagonists	  have	   recently	  been	  
reviewed	  by	  Oishi	  and	  Fujii	  [47].	  
	  
It	  should	  be	  noted	  that	  subsequent	  pharmacodynamics	  studies	  of	  some	  of	  these	  
compounds	  showed	  that	  T140	  had	  inverse	  agonistic	  properties	  in	  addition	  to	  the	  
antagonistic	  actions	  on	  CXCL12-­‐induced	  CXCR4	  activity,	  and	  that	  AMD3100	  and	  
ALX40-­‐4C	  were	  weak	  partial	  agonists	  [48].	  
	  
While	   progress	   had	   been	   made	   for	   both	   the	   polypeptide	   antagonists	   and	   the	  
functional	   mimetics	   during	   the	   1990s,	   the	   foundation	   for	   rational	   design	   of	  
topographical	   (type-­‐III)	   mimetics	   was	   not	   laid	   until	   2003,	   when	   Fujii	   et	   al.	  
reported	   a	   series	   of	   cyclic	   pentapeptides	   as	   potent	   CXCR4	   antagonists	   [49].	  
These	   small-­‐molecule	   peptides	   (MW	   =	   729	   Da)	   bridged	   the	   gap	   between	   the	  
large	   polypeptide	   antagonists	   (MW	   >	   2000	   Da)	   and	   the	   small-­‐molecule	  
functional	  mimetics,	  and	  are	  further	  discussed	  in	  section	  4.1.	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3. MOLECULAR	   INTERACTIONS	   BETWEEN	   CXCR4	   AND	   ITS	   KEY	   PEPTIDE	  
LIGANDS	  
	  
The	  7TM	  receptors	  are	  characterized	  by	  seven	  α-­‐helices	  (TM1-­‐7)	   that	  span	  the	  
cell	  membrane.	  The	  helices	  are	  connected	  by	  three	  extracellular	  loops	  (ECL1-­‐3)	  
and	  three	  intracellular	  loops	  (ICL1-­‐3)	  and	  flanked	  by	  an	  extracellular	  N-­‐terminus	  
and	  an	  intracellular	  C-­‐terminus;	  in	  some	  7TM	  receptors	  an	  additional	  helix	  (H8)	  
is	  found	  in	  the	  C-­‐terminus.	  
	  
Before	  the	  first	  X-­‐ray	  structures	  of	  CXCR4	  were	  reported,	  the	  only	  available	  7TM	  
structures	  were	   light-­‐activated	   (rhodopsin),	   aminergic,	   and	   nucleoside	   binding	  
receptors.	   Prior	   to	   the	   public	   release	   of	   the	   experimental	   CXCR4	   structures,	   a	  
community-­‐wide	  assessment	  (GPCR	  Dock	  2010)	  was	  conducted	  [50],	  where	  the	  
scientific	   community	   was	   challenged	   to	   predict	   the	   structures	   of	   these	   solved	  
complexes.	  The	  results	  of	  this	  assessment	  showed	  that	  the	  detailed	  structure	  of	  
CXCR4	   itself	   (and	   hence,	   the	   binding	   pocket)	   was	   quite	   difficult	   to	   accurately	  
model	  based	  on	  the	  already	  known	  7TM	  receptor	  structures	  [50].	  This	  was	  due	  
to	   several	   distinctive	   structural	   features	   in	   the	   X-­‐ray	   structures	   of	   CXCR4,	  
including	   shifting,	   rotation,	   and	  extension	  of	   transmembrane	  helices	   as	  well	   as	  
the	  folding/position	  of	  ECL2	  [5].	  Also,	  partly	  as	  a	  consequence,	  the	  prediction	  of	  
correct	  binding	  mode	  for	  the	  CXCR4	  antagonists	  by	  docking	  to	  homology	  models	  
proved	   extremely	   difficult,	   especially	   for	   the	   large	   CVX15	   ligand	   [50].	   For	   this	  
reason,	   we	   herein	   limit	   the	   discussion	   to	   the	   X-­‐ray	   structures	   of	   CXCR4	   and	  
proposed	  peptide	  ligand:CXCR4	  complexes	  that	  are	  based	  on	  these	  experimental	  
structures,	  i.e.	  homology	  models	  published	  before	  2010	  are	  not	  considered.	  
	  
3.1. Experimental	  peptide	  ligand:CXCR4	  complexes	  
Two	   of	   the	   experimental	   CXCR4	   complexes	   published	   to	   date	   contain	   a	  
peptide/protein	   ligand:	   the	  CVX15:CXCR4	   co-­‐crystal	   structure	   (PDB:	  3OE0)	   [5]	  
and	  the	  vMIP-­‐II:CXCR4	  structure	  (PDB:	  4RWS)	  [6].	  The	  third	  ligand	  that	  has	  been	  
co-­‐crystallized	   with	   CXCR4	   is	   the	   small-­‐molecule	   isothiourea-­‐derivative	   IT1t	  
(PDB:	  3ODU)	  [5].	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Figure	  2.	  (A)	  Schematic	  presentation	  of	  the	  binding	  modes	  for	  the	  polypeptide	  antagonist	  CVX15	  
(green	  ribbon;	  PDB:	  3OE0)	  [5],	  the	  non-­‐peptide	  small-­‐molecule	  antagonist	  IT1t	  (ball-­‐and-­‐stick,	  
orange	  carbon	  atoms;	  PDB:	  3ODU)	  [5],	  and	  the	  viral	  chemokine	  antagonist	  vMIP-­‐II	  (red	  ribbon;	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PDB:	  4RWS)	  [6].	  For	  clarity,	  only	  the	  receptor	  structure	  of	  the	  CVX15:CXCR4	  complex	  (white	  
ribbons;	  PDB:	  3OE0)	  is	  shown.	  The	  figure	  was	  created	  with	  Maestro	  [51]	  by	  superimposing	  the	  
Cα-­‐atoms	  of	  the	  transmembrane	  bundle	  (residues	  34-­‐62,	  72-­‐99,	  105-­‐139,	  145-­‐174,	  193-­‐224,	  239-­‐
266,	  273-­‐301).	  (B)	  Ligand	  interaction	  diagram	  (LID)	  for	  the	  three	  N-­‐terminal	  residues	  (Arg1-­‐
Arg2-­‐1-­‐Nal3)	  of	  CVX15.	  (C)	  LID	  for	  IT1t.	  (D)	  LID	  for	  the	  four	  N-­‐terminal	  residues	  (Leu1-­‐Gly2-­‐Ala3-­‐
Ser4)	  of	  vMIP-­‐II.	  (E)	  Legend	  for	  LID.	  The	  LIDs	  were	  created	  with	  Maestro	  [51]	  using	  a	  cutoff	  of	  3	  
Å.	  
	  
CVX15	  is	  a	  16-­‐mer	  opened	  analog	  of	  the	  head-­‐to-­‐tail	  cyclized	  POL-­‐3026	  (Figure	  
1A)	  [52],	  which	  was	  developed	  from	  the	  14-­‐mer	  “prototype”	  polypeptide	  CXCR4	  
antagonist	  T140.	   β-­‐Turns	   are	   known	   to	  be	  binding	  motifs	   for	   peptidergic	   7TM	  
receptors	   [53],	   and	   NMR	   studies	   have	   previously	   shown	   that	   T140	   indeed	  
contains	   a	   β-­‐turn	   around	   positions	   8	   and	   9	   (D-­‐Lys8-­‐Pro9)	   [54].	   However,	   the	  
crystal	   structure	   of	   the	   CVX15:CXCR4	   complex	   (Figure	   2A)	   shows	   that	   the	  
corresponding	  D-­‐Pro8-­‐Pro9	  turn	  of	  CVX15	  is	  not	  embedded	  in	  the	  ligand	  binding	  
pocket	   within	   the	   transmembrane	   bundle,	   but	   is	   oriented	   towards	   the	  
extracellular	  side.	  As	  the	  24	  N-­‐terminal	  residues	  of	  CXCR4	  are	  missing	  in	  the	  co-­‐
crystal	   structure	   due	   to	   lack	   of	   interpretable	   densities,	   this	   complex	   does	   not	  
reveal	  all	  potential	  interactions	  between	  CVX15	  and	  the	  CXCR4	  N-­‐terminus.	  The	  
receptor	  interactions	  are	  mainly	  found	  within	  the	  so-­‐called	  major	  binding	  pocket	  
(delimited	  by	  TMs	  3-­‐6),	  and	  are	  formed	  by	  the	  N-­‐	  and	  C-­‐terminal	  ends	  of	  CVX15	  
(Figure	  2B),	  which	   contain	   the	   four	  pharmacophoric	   residues	   (Arg2,	  Nal3,	  Tyr5,	  
and	   Arg14)	   of	   the	   polypeptide	   antagonists	   [55].	   The	   CVX15:CXCR4	   complex	   is	  
highly	  relevant	  for	  further	  development	  of	  the	  T140-­‐derived	  CXCR4	  antagonists,	  
including	  the	  cyclopentapeptides	  (section	  4.1).	  
	  
In	   contrast	   to	   CVX15,	   which	  mainly	   binds	   within	   the	  major	   binding	   pocket	   of	  
CXCR4,	   the	  small-­‐molecule	  non-­‐peptide	  antagonist	   IT1t	  binds	  within	   the	  minor	  
binding	  pocket,	  which	  is	  delimited	  by	  TMs	  1,	  2,	  3,	  and	  7	  (Figure	  2C).	  Based	  on	  the	  
different	   binding	   modes	   of	   the	   polypeptide	   CVX15	   and	   the	   non-­‐peptide	  
antagonist	  IT1t,	  it	  is	  tempting	  to	  classify	  the	  major	  and	  minor	  binding	  pocket	  of	  
CXCR4	   as	   the	   “peptide”	   and	   “non-­‐peptide”	   pocket,	   respectively;	   however,	   they	  
should	  not	  be	  considered	  as	  such.	  Early	  mutagenesis	  studies	  in	  CXCR4	  predicted	  
the	  major	  binding	  pocket	  to	  be	  the	  main	  pocket	  for	  the	  binding	  of	  bicyclams	  and	  
	   12	  
monocyclams,	  exemplified	  by	  AMD3100	  and	  AMD3465,	  respectively	  [56-­‐61].	   In	  
both	  ligand	  classes,	  Asp171	  (TM4)	  was	  suggested	  to	  be	  the	  anchor	  point	  for	  one	  
cyclam	   ring.	   For	   the	   bicyclams,	   the	   other	   cyclam	   ring	   was	   suggested	   to	   be	  
sandwiched	   between	   TM6	   and	   TM7	   (Asp262	   and	   Glu288),	   whereas	   the	   non-­‐
cyclam	  end	  of	   the	  monocyclams	   -­‐	   in	  AMD3465,	   a	   simple	  N-­‐pyridinylmethylene	  
moiety	  –	  had	  an	  expanded	  interaction	  pattern	  that	  also	  included	  residues	  located	  
in	   the	   extracellular	   segments	   of	   TM6	   (Ile259)	   and	   TM7	   (His281)	   [60].	   Also,	   a	  
recent	  binding	  mode	  study	  of	  the	  non-­‐peptide	  small-­‐molecule	  CXCR4	  antagonist	  
AMD11070	   showed	   that	   poses	   generated	   by	   docking	   to	   the	   3OE0	   (peptide	  
ligand)	   structure	  were	   in	   better	   agreement	  with	   experimental	   data	   than	  poses	  
generated	  with	  the	  3ODU	  (non-­‐peptide)	  structure,	  and	  that	  Asp171	  (TM4)	  in	  the	  
major	  binding	  pocket	  was	  involved	  in	  strong	  interactions	  with	  this	  non-­‐peptide	  
ligand	  [62].	  	  
	  
vMIP-­‐II	   is	   a	   viral	   chemokine	   that	   is	   secreted	  by	  human	  herpesvirus	  8,	   and	  has	  
been	  shown	   to	  be	  a	  potent	  antagonist	   for	   several	  human	  chemokine	  receptors,	  
including	   CXCR4	   [63].	   Activation	   of	   chemokine	   receptors	   by	   their	   endogenous	  
chemokine	   agonists	   is	   generally	   considered	   to	   be	   a	   two	   step	   process,	   where	  
separate	  regions	  of	  the	  large	  chemokine	  ligand	  are	  involved	  in	  initial	  binding	  to	  
and	  activation	  of	   the	  receptor;	   the	  corresponding	  receptor	  regions	  are	  referred	  
to	  as	  chemokine	  recognition	  site	  (CRS)	  1	  and	  2	  [64].	  	  
	  
The	  successful	  crystallization	  of	  vMIP-­‐II:CXCR4	  was	  achieved	  by	   formation	  of	  a	  
covalent	   complex	   by	   disulfide-­‐trapping	   of	   the	   engineered	   cysteine	   mutants	  
D187C	  (CXCR4)	  and	  W5C	  (vMIP-­‐II)	  [6].	  The	  X-­‐ray	  structure	  shows	  that	  the	  vMIP-­‐
II	  core	  (specifically	  residues	  13-­‐16	  and	  49-­‐51)	  makes	  extensive	  contacts	  with	  the	  
CXCR4	  N-­‐terminus,	  while	   the	   vMIP-­‐II	   N-­‐terminus	   (residues	   1-­‐10)	   reaches	   into	  
the	  binding	  pocket	  within	  the	  transmembrane	  bundle.	  Specifically,	  the	  structure	  
identifies	   residues	   23-­‐27	   in	   the	   CXCR4	   N-­‐terminus	   as	   CRS1	   (the	   ultimate	   N-­‐
terminal	   residues	  1-­‐22	  are	  not	  visible	   in	   the	  structure),	  and	  CXCR4	  residues	   in	  
TM2	   (Trp94,	   Asp97),	   TM3	   (His113),	   ECL2	   (Asp187),	   TM6	   (Asp262),	   and	   TM7	  
(Glu277,	   His281,	   Glu288)	   as	   key	   interaction	   partners	   for	   the	   N-­‐terminal	   tip	  
(residues	   1-­‐7)	   of	   vMIP-­‐II,	   i.e.	   CRS2	   (Figure	   2D).	   Also,	   there	   is	   an	   intermediate	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region	   (termed	   CRS1.5)	   that	   involves	   additional	   interactions	   between	   the	   N-­‐
terminus	  of	  CXCR4	  (residues	  27-­‐31)	  and	  vMIP-­‐II	   (residues	  8-­‐12).	   Interestingly,	  
as	   the	   N-­‐terminal	   tip	   of	   vMIP-­‐II	   mainly	   occupies	   the	   minor	   binding	   pocket	   of	  
CXCR4,	  the	  spatial	  overlap	  between	  vMIP-­‐II	  and	  CVX15	  is	  quite	  limited;	  instead,	  
the	  ultimate	  N-­‐terminal	  residues	  of	  vMIP-­‐II	  overlap	  with	  the	  small-­‐molecule	  IT1t	  
that	  binds	  to	  the	  same	  receptor	  region	  (Figure	  2A).	  
	  
Even	  if	  the	  complex	  between	  the	  viral	  chemokine	  antagonist	  vMIP-­‐II	  and	  CXCR4	  
represents	  an	  inactive	  receptor	  state,	  the	  X-­‐ray	  structure	  still	  provides	  valuable	  
insight	   into	   the	   molecular	   recognition	   between	   CXCR4	   and	   its	   endogenous	  
chemokine	   agonist	   CXCL12	   (section	   3.2).	   The	   structure	   is	   also	   a	   valuable	  
foundation	  for	  design/optimization	  of	  peptide/peptidomimetic	  antagonist	  based	  
on	  vMIP-­‐II	  fragments,	  e.g.	  the	  Trp5-­‐His6-­‐Arg7	  based	  peptides	  reported	  by	  Portella	  
et	  al.	  (section	  4.3.2).	  
	  
3.2. Proposed	  CXCL12:CXCR4	  complexes	  
As	   activation	   of	   CXCR4	   by	   its	   68-­‐mer	   protein	   ligand	   CXCL12	   is	   a	   key	   event	   in	  
several	   pathological	   processes,	   including	   cancer	   metastasis,	   rational	   design	   of	  
e.g.	   anti-­‐cancer	   drugs	   would	   benefit	   from	   a	   better	   understanding	   of	   the	  
CXCL12:CXCR4	  interactions	  and	  activation	  mechanism.	  	  
	  
Despite	   the	   huge	   structural	   differences	   between	   the	   ligands	   for	   class	   A	   7TM	  
receptors,	   it	   is	   generally	   acknowledged	   that	   all	   class	  A	   receptor	   subclasses	   are	  
activated	  by	   the	  same	  overall	  helical	  movements	   [65].	  At	  present,	  >100	  crystal	  
structures	  of	  ~20	  7TM	  receptors	  have	  been	   reported	   [66].	   Some	  of	   these	  have	  
been	   crystallized	   in	   an	   active	   conformation,	   thereby	   shedding	   light	   on	   the	  
structural	   requirements	   for	   receptor	   activity,	   including	   the	   conformation	   of	  
molecular	  micro-­‐switches.	   For	   a	   recent	   review	  on	  activation	  of	  7TM	  receptors,	  
see	  reference	  [67].	  
	  
After	  the	  identification	  of	  CXCL12	  as	  the	  endogenous	  agonist	  for	  CXCR4	  [12],	  the	  
first	  NMR	  [41]	  and	  X-­‐ray	  [68]	  structures	  of	  CXCL12	  soon	  followed.	  The	  solution	  
structure	   [41]	   revealed	   that	   CXCL12	   adopts	   the	   common	   tertiary	   chemokine-­‐
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fold,	  with	  a	  flexible	  N-­‐terminus,	  an	  extended	  loop	  (N-­‐loop),	  three	  antiparallel	  β-­‐
strands	  (β1-­‐β3)	  connected	  by	  two	  β-­‐turns,	  and	  an	  α-­‐helix,	  which	  is	  connected	  to	  
the	  β3-­‐strand	  by	  another	  β-­‐turn	  (later	  referred	  to	  as	  the	  50s	   loop).	   [65][70-­‐73]	  
The	  “two-­‐step”	  activation	  model	  has	  also	  been	  proposed	  for	  CXCL12:CXCR4,	  and	  
early	   functional	   studies	   of	   CXCL12-­‐analogs	   indicated	   that	   the	   RFFESH-­‐motif	  
(residues	  12-­‐17)	   in	   the	  N-­‐loop	  had	  a	  key	   role	   in	   the	   initial	   binding	   step	   (CRS1	  
interaction),	  while	   the	   flexible	  N-­‐terminal	  region	  (residues	  1-­‐8),	  especially	  Lys1	  
and	   Pro2,	   was	   responsible	   for	   receptor	   activation	   (CRS2	   interaction)	   [41].	  
However,	   it	   should	   be	   noted	   that	   the	   “two-­‐step”	   model	   probably	   is	   a	  
simplification,	  as	   several	  minor	  steps	  could	  be	  anticipated	   to	   take	  place	  during	  
chemokine	  binding	  and	  subsequent	  receptor	  activation	  [69],	  as	  shown	  for	  other	  
class	  A	  receptors	  [70-­‐72].	  Accordingly,	  advanced	  NMR	  studies	  have	  shown	  that	  
large	  parts	  of	  the	  CXCL12	  core	  structure,	  including	  the	  N-­‐loop,	  the	  50s	  loop,	  and	  
the	  β-­‐sheet,	  are	  involved	  in	  the	  initial	  binding	  step	  [73].	  	  
	  
With	   respect	   to	   the	   stoichiometry	   of	   the	   CXCL12:CXCR4	   complex,	   several	  
different	  alternatives	  have	  been	  envisioned	  (1:1,	  1:2,	  2:1,	  2:2);	  however,	  recent	  
studies	  by	  Kufareva	  et	  al.	  show	  that	  the	  1:1	  complex	  is	  the	  functional	  unit	  [6,	  74].	  	  
	  
In	  their	  report	  of	  the	  first	  X-­‐ray	  structures	  of	  CXCR4	  [5],	  Wu	  et	  al.	  suggested	  that	  
the	  co-­‐crystallized	  ligands	  CVX15	  and	  IT1t,	  at	  least	  to	  some	  extent,	  occupied	  the	  
binding	  site	  of	   the	  activating	  CXCL12	  N-­‐terminus,	   i.e.	  CRS2.	  Five	  computational	  
models	  of	  the	  CXCL12:CXCR4	  interaction	  have	  since	  been	  reported,	  four	  of	  which	  
have	  been	  based	  on	  the	  CVX15/IT1t	  X-­‐ray	  structures.	  Xu	  et	  al.	  combined	  protein-­‐
protein	   docking,	   molecular	   dynamics	   (MD)	   simulations,	   and	   free	   energy	  
calculations,	  starting	  from	  one	  CXCL12	  structure	  and	  one	  CXCR4	  structure	  [75].	  
Tamamis	   and	   Floudas	   published	   a	   more	   extensive	   study,	   starting	   from	   22	  
CXCL12	   structures	   and	   17	   CXCR4	   structures	   [76].	   In	   both	   these	   studies,	   the	  
missing	  N-­‐terminal	   residues	  of	   the	  CXCR4	  X-­‐ray	  structure	  were	  constructed	  by	  
utilizing	   the	  NMR	   structure	   of	   CXCL12	   complexed	  with	   the	   CXCR4	  N-­‐terminus	  
[77].	   Costantini	   et	   al.	   docked	   a	   crystallographic	   CXCL12	   structure	   to	   a	   CXCR4	  
structure	   where	   the	   missing	   N-­‐terminus	   was	   modeled	   based	   on	   a	   rhodopsin	  
structure	   [78].	   The	   Abagyan/Handel	   group	   first	   generated	   a	   model	   of	   the	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CXCL12:CXCR4	   complex	   by	   employing	   an	   engineered	   and	   experimentally	  
validated	  disulfide	  bond	  (CXCL12	  S16C	  to	  CXCR4	  K25C)	  as	  restraint	  [74].	  Based	  
on	   their	   experimental	   vMIP-­‐II:CXCR4	   structure,	   the	   same	   group	   recently	  
proposed	  a	  further	  refined	  CXCL12:CXCR4	  model,	  using	  the	  position	  of	  the	  vMIP-­‐
II	   core	   as	   a	   guide	   for	   the	   CRS1	   interaction	   [6].	   Both	   models	   from	   the	  
Abagyan/Handel	   group	   contain	   a	   truncated	   CXCR4	  N-­‐terminus	   as	   no	   attempts	  
were	  made	  to	  construct	  the	  missing	  N-­‐terminal	  residues.	  
	  	  
Figure	   3A	   shows	   a	   schematic	   comparison	   of	   four	   of	   the	   CXCL12:CXCR4	  
complexes	  (we	  did	  not	  have	  access	  to	  the	  coordinates	  of	  the	  model	  proposed	  by	  
Costantini	   et	   al).	  While	   experimental	   data	   (e.g.	   from	   site-­‐directed	  mutagenesis	  
studies)	  have	  been	  considered	  in	  all	  cases,	  the	  figure	  clearly	  shows	  that	  there	  are	  
significant	   differences	   between	   the	   models,	   both	   with	   respect	   to	   interactions	  
between	   the	   CXCL12	   core	   and	   the	   extracellular	   domains	   of	   CXCR4	   (CRS1)	   and	  
the	   interactions	   between	   the	   CXCL12	   N-­‐terminus	   and	   the	   transmembrane	  
bundle	   (CRS2).	   Again,	   this	   reflects	   the	   difficulties	   in	  modeling	   binding	   of	   large	  
and	  complex	  peptide/protein	  ligands	  to	  their	  receptors.	  	  
	   	  








Figure	  3.	  (A)	  Comparison	  of	  the	  CXCL12:CXCR4	  complexes	  suggested	  by	  Xu	  et	  al.	  (red)	  [75],	  
Tamamis	  and	  Floudas	  (green)	  [76],	  Kufareva	  et	  al.	  (blue)	  [74],	  and	  Qin	  et	  al.	  (orange)	  [6].	  For	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clarity,	  only	  the	  receptor	  structure	  of	  the	  complex	  proposed	  by	  Kufareva	  et	  al.	  (white	  ribbons)	  is	  
shown.	  The	  PDB-­‐files	  were	  kindly	  provided	  by	  Drs.	  Tingjun	  Hou,	  Christodoulos	  A.	  Floudas,	  and	  
Irina	  Kufareva	  (two	  structures).	  The	  figure	  was	  created	  as	  described	  in	  Figure	  2A.	  (B-­‐D)	  Ligand	  
interaction	  diagrams	  for	  the	  eight	  N-­‐terminal	  CXCL12	  residues	  (KPVSLSYR)	  in	  the	  models	  by	  Xu	  
et	  al.	  (B),	  Tamamis	  and	  Floudas	  (C),	  and	  Qin	  et	  al.	  (D).	  The	  LIDs	  were	  created	  as	  described	  in	  
Figure	  2.	  
	  
The	   model	   proposed	   by	   Xu	   et	   al.	   involves	   electrostatic	   interactions	   between	  
Asp262/Glu277	   and	   Lys271	   of	   CXCR4	   with	   Arg12	   and	   Glu15	   of	   CXCL12,	  
respectively,	  thus	  identifying	  the	  top	  of	  TM6	  and	  TM7,	  including	  ECL3,	  as	  CRS1.	  
With	   respect	   to	   CRS2	   (Figure	   3B),	   the	   model	   suggests	   that	   the	   N-­‐terminus	   of	  
CXCL12	   is	   curled	  up	   in	   the	   transmembrane	  binding	  pocket,	  with	   the	   tip	   of	   the	  
loop	  pointing	  up	  towards	  the	  extracellular	  receptor	  domains.	  Arg8	  at	  the	  base	  of	  
the	  CXCL12	  N-­‐terminus	  is	  involved	  in	  a	  salt	  bridge	  with	  Asp187	  (ECL2),	  while	  H-­‐
bond	   interactions	   between	  Val3/Ser4	   and	  Glu288	   (TM7)	   anchor	   CXCL12	   to	   the	  
bottom	  of	  the	  pocket.	  However,	  Lys1	  of	  CXCL12,	  which	  is	  known	  to	  be	  important	  
for	  activation	  of	  CXCR4,	  reaches	  out	  of	  the	  pocket	  and	  interacts	  with	  Glu32	  in	  the	  
CXCR4	  N-­‐terminus.	  	  
	  
In	   contrast,	   Tamamis	   and	   Floudas	   identified	   the	   N-­‐terminus	   and	   ECL2	  
(connecting	   TM4	   and	  TM5)	   of	   CXCR4	   as	   CRS1,	   specifically	   residues	   Glu2,	   Ile6-­‐
Tys12,	  Glu14,	  Met16,	  and	  Tyr190-­‐Asp193.	  Salt	  bridges	  were	  seen	  between	  Arg12	  
of	   CXCL12	   and	  Glu2,	   Tys7,	   and	  Asp193	   of	   CXCR4.	   They	   also	   identified	  Asp187	  
(ECL2)	   as	   the	   main	   interaction	   partner	   for	   Arg8	   of	   CXCL12	   (Figure	   3C),	   but	  
suggest	   that	   the	   N-­‐terminus	   points	   straight	   down	   into	   the	   helical	   bundle,	   and	  
that	   residues	   Lys1-­‐Leu5	   are	   practically	   buried	   in	   the	   transmembrane	   pocket	  
(CRS2).	  Here,	  Lys1	  forms	  salt	  bridges	  with	  both	  Asp171	  (TM4)	  and	  Glu288	  (TM7)	  
at	  the	  bottom	  of	  the	  pocket.	  	  
	  
The	  model	  recently	  proposed	  by	  Qin	  et	  al.	  [6]	  appears	  to	  be	  the	  most	  mature,	  as	  
structural	   information	   from	  the	  experimental	  vMIP-­‐II:CXCR4	  complex	  has	  been	  
employed	   to	   generate	   the	   CXCL12:CXCR4	   complex.	   This	   model	   identifies	   the	  
CXCR4	  N-­‐terminus	   and	   the	   top	   of	   TM6	   and	  TM7,	   including	  ECL3,	   as	   CRS1/1.5.	  
The	  proximal	  N-­‐terminus	  (residues	  21-­‐25;	  residues	  1-­‐20	  are	  not	  included	  in	  the	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model)	   is	   in	   extensive	   contact	   with	   several	   domains	   in	   the	   CXCL12	   core,	  
including	   the	   N-­‐loop	   and	   the	   β2-­‐β3	   loop.	   At	   the	   interface	   between	   the	  
extracellular	   receptor	   domains	   and	   the	   transmembrane	   pocket	   (CRS1.5)	  
electrostatic	   interactions	   are	   found	   between	   Asp262:Arg8	   and	   Glu277:Arg12.	  
With	   respect	   to	   CRS2,	   Qin	   et	   al.	   suggest	   that	   the	   N-­‐terminus	   of	   CXCL12	   is	  
oriented	   towards	   the	   minor	   binding	   pocket	   (Figure	   3D).	   Specifically,	   Lys1	   of	  
CXCL12	   forms	   salt	   bridges	   with	   Asp97	   (TM2)	   via	   the	   positively	   charged	   N-­‐
terminal	  amino	  group,	  and	  with	  Glu288	  (TM7)	  via	   the	  side	  chain	  amino	  group.	  
The	  side	  chains	  of	  Ser4	  and	  Tyr7	  are	  both	  involved	  in	  H-­‐bonds	  to	  Asp187	  (ECL2).	  
	  
While	   these	  models	   of	   the	   CXCL12:CXCR4	   complex	   are	   intriguing,	   it	   should	   be	  
noted	   that	   the	  experimental	  CXCR4	  structures	   that	  have	  been	  used	   to	  generate	  
them	   are	   in	   inactive	   (antagonist-­‐bound)	   states,	   and	   thus	   not	   ideally	   suited	   as	  
templates	   for	   modeling	   of	   the	   active	   (agonist-­‐bound)	   state	   of	   CXCR4.	   In	   the	  
absence	   of	   further	   structural	   knowledge	   about	   the	   activated	   CXCR4	   state,	   it	   is	  
difficult	   to	   judge	   how	   well	   the	   proposed	   complexes	   describe	   the	   “true”	  
CXCL12:CXCR4	   interactions.	   Consequently,	   rational	   design	   of	   small-­‐molecule	  
peptidomimetic	  ligands	  based	  on	  short	  CXCL12-­‐motifs	  still	  remains	  a	  challenging	  
task.	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3.3. Proposed	  HIV-­‐1	  V3:CXCR4	  complexes	  	  
By	  now,	  the	  role	  of	  CXCR4	  as	  co-­‐receptor	  for	  HIV-­‐1	  entry	  into	  human	  cells	  is	  well	  
established	  [79].	  Specifically,	  this	  involves	  binding	  of	  the	  third	  variable	  loop	  (V3)	  
of	   the	   HIV-­‐1	   envelope	   glycoprotein	   gp120	   to	   CXCR4.	   Thus,	   understanding	   the	  
detailed	  molecular	  interactions	  between	  the	  V3	  loop	  and	  CXCR4	  is	  important	  for	  
development	  of	  small-­‐molecule	  anti-­‐HIV	  drugs.	  	  
	  
The	  V3	  loop	  consists	  of	  a	  base,	  a	  stem,	  and	  a	  tip,	  and	  when	  the	  first	  structures	  of	  
V3	   were	   published,	   it	   was	   believed	   that	   the	   base	   and	   stem	   bind	   to	   the	   N-­‐
terminus	  of	  the	  HIV-­‐1	  co-­‐receptors	  CXCR4/CCR5	  while	  the	  highly	  conserved	  V3	  
tip	   (GPGR	  β-­‐turn	  motif)	   interacts	  with	   the	   extracellular	   loops	   [80,	   81],	   i.e.	   that	  
binding	   did	   not	   involve	   the	   transmembrane	   pocket.	   However,	   the	   first	   X-­‐ray	  
structures	  of	  CXCR4	  provided	  some	  indications	  that	  the	  V3	  loop	  could	  penetrate	  
down	   into	   this	   pocket	   [5].	   Two	   computational	   models	   of	   the	   V3:CXCR4	  
interaction	   have	   since	   been	   proposed	   [82,	   83],	   both	   of	   which	   involve	   the	  
transmembrane	  pocket	  (Figure	  4A).	  
	  
In	   the	   supporting	   information	   of	   their	   report	   of	   the	   X-­‐ray	   structure	   of	   CCR5,	  
which	   is	   the	   other	   co-­‐receptor	   for	   HIV	   entry,	   Tan	   et	   al.	   presented	   possible	  
structural	   complexes	   for	   the	  HIV	  V3	   loop	  bound	   to	  CXCR4	  and	  CCR5	   [82].	  The	  
V3:CXCR4	  complex	  was	  generated	  by	  docking	  of	   the	   terminally	   constrained	  20	  
residue	   peptide	   fragment	   TRKR306IR308IQR311GPGR315AFVTIGK322,	  
corresponding	  to	  residues	  303-­‐322	  in	  the	  V3	  loop	  of	  the	  T-­‐tropic	  (CXCR4-­‐using)	  
HIV-­‐1	  strain	  HXBc2.	  In	  the	  suggested	  V3:CXCR4	  complex	  (Figures	  4A	  and	  B),	  the	  
following	   salt-­‐bridges	   were	   observed:	   Arg306/Lys322	   to	   Asp193,	   Arg308	   to	  
Asp262/Glu277,	   Arg311	   to	   Asp97/Asp187,	   and	   Arg315	   to	   Asp171.	   However,	   it	  
should	   be	   noted	   that	   the	   N-­‐terminal	   residues	   that	   are	   missing	   in	   the	   X-­‐ray	  
structures	  of	  the	  receptor	  were	  not	  taken	  into	  consideration.	  
	   	  








Figure	  4.	  (A)	  Comparison	  of	  the	  HIV-­‐1	  V3:CXCR4	  complexes	  suggested	  by	  Tan	  et	  al.	  [82]	  (green)	  
and	  Tamamis	  and	  Floudas	  [83]	  (red).	  The	  figure	  was	  created	  as	  described	  in	  Figure	  2A	  [53].	  The	  
PDB-­‐files	  were	  kindly	  provided	  by	  Professors	  Beili	  Wu	  and	  Christodoulos	  A.	  Floudas,	  
respectively.	  (B)	  Ligand	  interaction	  diagram	  (LID)	  for	  the	  conserved	  HIV-­‐1	  V3	  GPGR315	  motif	  in	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the	  model	  by	  Tan	  et	  al.	  (C)	  LID	  for	  the	  same	  GPGR18	  motif	  in	  the	  model	  by	  Tamamis	  and	  Floudas.	  
The	  LIDs	  were	  created	  as	  described	  in	  Figure	  2.	  
	  
Tamamis	  and	  Floudas	  have	  recently	  proposed	  a	  model	  of	  the	  V3:CXCR4	  complex	  
based	   on	   a	   more	   comprehensive	   protocol,	   which	   included	   docking,	   MD	  
simulations	  and	  free	  energy	  calculations	  [83].	  They	  used	  the	  entire	  V3	  sequence	  
(CTR3PNNNTRK10RVSLGPGR18VWYTTGQIVGDIR31KAHC)	   of	   a	   dual-­‐tropic	  
(CXCR4-­‐	   and	   CCR5-­‐using)	   HIV	   strain,	   and	   also	   constructed	   the	   missing	   N-­‐
terminal	  of	  CXCR4.	  Analysis	  of	  the	  final	  complex	  (Figures	  4A	  and	  C)	  showed	  that	  
most	   of	   the	  V3	   loop	  was	  buried	   in	   the	   receptor,	  with	   the	  N-­‐terminal	   of	   CXCR4	  
curved	   around	   V3.	   Extensive	   contacts	   were	   found	   for	   all	   TMs,	   although	   to	  
different	   extents,	   and	   also	   for	   all	   extracellular	   domains	   except	   ECL1.	   The	  
strongest	   intermolecular	   interaction	   in	   the	   entire	   complex	  was	   the	   salt	   bridge	  
between	  Arg18	   in	   V3	   and	  Asp171	   (TM4)	   and	  Glu288	   (TM7)	   (Figure	   4C).	   Other	  
key	  V3:CXCR4	  interactions	  included	  Arg3:Asp22/Glu268	  (N-­‐terminus	  and	  ECL3,	  
respectively),	   Lys10:Asp193	   (ECL2),	   and	   Arg31:Glu14/Asp20	   (both	   in	   N-­‐
terminus),	   i.e.	   salt	   bridges	   between	   positively	   charged	   V3	   residues	   and	  
negatively	  charged	  CXCR4	  residues.	  
	  
Due	   to	   the	  differences	   in	   length	   and	   sequence	  of	   the	  V3	   loops	  used	   in	   the	   two	  
studies,	   it	   is	   difficult	   to	   compare	   the	   specific	   residue	   interactions	   directly.	  
However,	  as	  the	  overlay	  of	  the	  two	  complexes	  (Figure	  4A)	  shows,	  the	  conserved	  
GPGR	  tip	  is	  positioned	  similarly	  in	  both	  cases,	  with	  the	  Arg	  residue	  anchored	  to	  
Asp171	  (TM4)	  (Figures	  4B	  and	  C).	  Still,	   the	  orientation	  of	  the	  stem	  and	  base	  of	  
the	  V3	  loops	  differ	  significantly.	  
	  
The	   ligand-­‐receptor	   complexes	   for	   CXCL12:CXCR4	   (Figure	   3C)	   and	   V3:CXCR4	  
(Figure	  4C)	  published	  by	  Tamamis	  and	  Floudas	  show	  a	  substantial	  overlap	  of	  the	  
binding	  sites,	  where	  the	  N-­‐terminus	  of	  CXCL12	  and	  the	  tip	  of	  the	  V3	  loop	  occupy	  
the	  same	  area.	  Specifically,	  Lys1	  of	  CXCL12	  and	  Arg18	  of	  the	  V3	  loop	  both	  interact	  
with	  Asp171	  (TM4)	  and	  Glu288	  (TM7).	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As	  is	  apparent	  from	  the	  above,	  the	  predominance	  of	  negatively	  charged	  residues	  
in	   the	   extracellular	   regions	   and	   the	   transmembrane	   binding	   pocket	   of	   CXCR4	  
means	   that	   the	   molecular	   interactions	   are	   dominated	   by	   salt	   bridges	   with	  
positively	   charged	   residues	   in	   the	   peptide	   ligands.	   For	   peptide	   ligands	   in	   the	  
major	   binding	   pocket	   of	   CXCR4,	   Asp171	   (TM4)	   is	   typically	   the	   key	   interaction	  
site	   for	  a	   ligand	  arginine	  residue.	  Asp171	  has	  also	  been	  shown	  to	  be	  an	  anchor	  
residue	   for	   the	   small-­‐molecule	   functional	   mimetics	   AMD3100	   [58],	   AMD3465	  
[60]	  and	  AMD11070	  [62].	  Ligands	  in	  the	  minor	  pocket	  normally	  engage	  in	  a	  salt	  
bridge	  to	  Asp97	  (TM2)	  and/or	  the	  nearby	  Asp187	  (ECL2).	  Glu288	  (TM7),	  which	  
sits	  centrally	  and	  bridges	  the	  major	  and	  minor	  pocket,	  is	  implicated	  in	  all	  of	  the	  
suggested	   binding	   modes	   for	   peptide	   CXCR4	   ligands	   (Figures	   3	   and	   4).	   This	  
residue	   (GluVII:06)	   is	   highly	   conserved	   in	   the	   chemokine	   receptor	   family,	   and	  
has	   been	   proposed	   to	   serve	   as	   an	   anchor	   point	   for	   positively	   charged	   small-­‐
molecule	  ligands	  for	  chemokine	  receptors	  [84].	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4. SMALL-­‐MOLECULE	   PEPTIDE	   AND	   PEPTIDOMIMETIC	   CXCR4	  
ANTAGONISTS	  	  
	  
The	   cyclopentapeptide	   CXCR4	   antagonists	   are	   especially	   interesting	   lead	  
compounds	   since	   cyclic	  pentapeptides	   are	  known	   to	  mimic	  peptide	   turns	   [85].	  
Such	  reverse-­‐turn	  motifs	  appear	  to	  be	  a	  universal	  ligand	  recognition	  element	  for	  
peptidergic	  7TM	  receptors	  [53],	  and	  the	  HIV	  V3:CXCR4	  interaction	  (section	  3.3)	  
indeed	   involves	  a	  β-­‐turn	  motif.	  Thus,	   the	  cyclopentapeptide	  CXCR4	  antagonists	  
provide	   an	   excellent	   starting	   point	   for	   rational	   design	   of	   topographical	   β-­‐turn	  
mimetics,	   and	   now	   that	   experimental	   structures	   of	   CXCR4	   have	   become	  
available,	  further	  progress	  in	  this	  field	  is	  expected.	  
	  
Marshall	   has	   proposed	   a	   6-­‐step	   hierarchical	   approach	   to	   rational	   design	   of	  
peptidomimetics	  from	  a	  parent	  bioactive	  peptide	  [86]:	  	  
	  
(1)	  Identify	  critical	  side	  chain	  residues	  (alanine	  scan)	  
(2)	  Define	  active	  core	  (size	  reduction)	  
(3)	   Define	   local	   conformational	   parameters,	   e.g.	   probable	   turns	   (D-­‐amino	   acid	  
scan,	  unusual	  amino	  acid	  scan)	  	  
(4)	   Generate	   active	   constrained	   analogs	   (cyclization,	   introduction	   of	   turn	  
mimetics,	  amide	  bond	  modification)	  	  
(5)	   Generate	   hypothesis	   for	   receptor-­‐bound	   conformation	   (conformational	  
analysis,	  physical	  studies)	  	  
(6)	  Arrive	  at	  constrained	  peptidomimetic	  analogs	  (design	  novel	  compounds	  that	  
mimic	  the	  critical	  3D	  elements)	  	  
	  
In	  this	  section,	  we	  first	  summarize	  the	  extensive	  studies	  of	  the	  cyclopentapeptide	  
CXCR4	   antagonists	   (roughly	   corresponding	   to	   steps	   1-­‐5	   above,	   but	   not	  
performed	   in	   this	   exact	   order)	   and	   then	   describe	   the	   attempts	   that	   have	   been	  
made	  to	  exploit	  this	   information	  for	  design	  of	  peptidomimetic	  analogs	  (step	  6).	  
Finally,	   other	   small-­‐molecule	   peptide	   and	   peptidomimetic	   CXCR4	   antagonists,	  
not	  inspired	  by	  the	  cyclopentapeptides,	  are	  discussed.	  
	  
	   24	  
4.1. Cyclic	  pentapeptides	  and	  derivatives	  
	  
4.1.1. Discovery	  of	  the	  cyclopentapeptide	  CXCR4	  antagonists	  
The	   cyclopentapeptide	   antagonists	   [49]	   (Figure	   5A)	   were	   developed	   from	   the	  
macrocyclic	  14-­‐mer	  polypeptide	  lead	  compound	  T140	  (Figure	  1A)	  [40],	  and	  the	  
downsizing	  strategy	  was	  based	  on	  combining	  the	  four	  pharmacophoric	  residues	  
of	  T140	  (Arg2,	  2-­‐Nal3,	  Tyr5,	  and	  Arg14)	  [55]	  with	  a	  Gly	  spacer	  to	  facilitate	  head-­‐to-­‐
tail	   cyclization.	   Of	   the	   192	   potential	   cyclopentapeptides	   (12	   sequences	   x	   16	  
stereoisomers),	   60	   compounds	   were	   synthesized	   and	   tested,	   resulting	   in	   the	  
identification	   of	   cyclo(-­‐L-­‐Arg1-­‐L-­‐Arg2-­‐L-­‐2-­‐Nal3-­‐Gly4-­‐D-­‐Tyr5-­‐),	   later	   known	   as	  
FC131	   (Figure	  5A)	   as	   the	  most	   potent	   CXCR4	   antagonist	  with	   IC50	   =	   0.004	  μM	  
(inhibition	  of	  125I-­‐SDF-­‐binding)	  and	  EC50	  =	  0.038	  μM	  (inhibition	  of	  HIV-­‐induced	  
pathogenicity)	  [49].	  The	  D-­‐Arg1-­‐epimer	  (later	  known	  as	  FC092)	  was	  also	  shown	  
to	  be	  a	  potent	  antagonist	  (IC50	  =	  0.008	  μM	  and	  EC50	  =	  0.11	  μM).	  Importantly,	  the	  
linear	   and	   capped	   analogs	   of	   the	   most	   potent	   cyclopentapeptides	   showed	  
significantly	  reduced	  activity.	  
	  
A	   solution	   structure	   for	   FC131	   based	   on	   1H-­‐NMR	   studies	   in	   DMSO	   was	   also	  
reported	   [49].	  While	   the	   exact	   spatial	   orientation	  of	   the	   relatively	   flexible	   side	  
chains	   could	   not	   be	   determined,	   the	   reported	   backbone	   conformation	   is	  
consistent	   with	   later	   NMR	   studies	   of	   the	   bioactive	   (receptor-­‐bound)	  
conformation	  for	  the	  cyclopentapeptide	  antagonists	  [87-­‐91].	  
	  
Thus,	   this	   key	   paper	   [49]	   demonstrated	   the	   simultaneous	   importance	   of	  
sequence,	  stereochemistry,	  and	  cyclic	  constraint	  for	  CXCR4	  antagonism,	  and	  also	  
revealed	   the	   presumed	   bioactive	   backbone	   conformation	   for	   the	   lead	  
cyclopentapeptide	  antagonist	  FC131.	  
	  
4.1.2. Backbone	  modifications	  
Retro-­‐inverso	  analogs.	  In	  addition	  to	  the	  “conformation-­‐based”	  and	  “sequence-­‐
based”	  libraries	  in	  the	  original	  paper	  [49],	  biological	  data	  were	  soon	  reported	  for	  
a	  third	  cyclopentapeptide	  library,	  consisting	  of	  retro-­‐inverso	  analogs	  (Figure	  5B)	  
[92].	   However, the	   retro-­‐inverso	   analog	  with	   highest	   potency	   (EC50	   =	   1.7	   μM)	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was	   19-­‐fold	   less	   potent	   than	   FC131	   (EC50	   =	   0.088	   μM).	   Also,	   the	   three	  
compounds	  with	   highest	   potency	   (EC50	   <	   5	   μM)	  were	   retro-­‐inverso	   analogs	   of	  
FC131	  stereoisomers	  with	  low	  potency	  (EC50	  >	  5	  μM).	  The	  generally	  low	  activity	  
of	   the	   retro-­‐inverso	  analogs	  compared	   to	  FC131	   indicates	  an	   important	   role	  of	  
the	  backbone	  amide	  bonds	  and/or	  conformation	  for	  CXCR4	  antagonism.	  
	  
	  
Figure	  5.	  Structures	  of	  (A)	  the	  lead	  cyclopentapeptide	  CXCR4	  antagonist	  FC131,	  (B)	  its	  retro-­‐
inverso	  analog,	  (C)	  the	  investigated	  amide	  bond	  isosteres,	  (D)	  the	  high-­‐affinity	  peptoid-­‐like	  
analog	  1	  reported	  by	  Demmer	  et	  al.	  [91],	  and	  (E)	  the	  two	  different	  classes	  of	  bridged	  cyclic	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Amide	   bond	   isosteres.	   Several	   studies	   on	   backbone	  modifications	   have	   since	  
followed,	  mainly	   by	   replacement	   of	   the	   amide	   bonds	  with	   isosteres,	   including	  
alkene	  [87,	  90,	  93],	  N-­‐alkyl	  [89,	  91],	  fluoroalkene	  [93,	  94],	  amidine	  [95],	  reduced	  
amide	  [87],	  and	  ethylene	  [90]	  isosteres	  (Figure	  5C).	  
	  
Of	  these,	  the	  most	  successful	  strategy	  in	  terms	  of	  activity	  has	  been	  introduction	  
of	   the	   amidine	   isostere	   [95].	   The	   most	   active	   analog	   contained	   an	   amidine	  
isostere	  in	  the	  Nal3-­‐Gly4	  fragment	  and	  had	  30-­‐fold	  higher	  affinity	  for	  CXCR4	  than	  
FC131	  (IC50-­‐values	  of	  4.2	  and	  126	  nM,	  respectively).	  The	  Gly4-­‐D-­‐Tyr5,	  Arg2-­‐Nal3,	  
and	  Arg1-­‐Arg2	  analogs	  were	  also	  highly	  active	  (IC50	  <	  16	  nM),	  while	  the	  D-­‐Tyr5-­‐
Arg1	   analog	   showed	   lower	   affinity	   (IC50	   =	   679	   nM)	   than	   FC131.	   The	   general	  
success	  of	  the	  amidine	  strategy	  was	  hypothesized	  to	  result	  from	  favorable	  ionic	  
interactions	   between	   the	   positively	   charged	   amidine	   group	   and	   negatively	  
charged	  Asp/Glu	  residues	  in	  the	  binding	  pocket.	  However,	  as	  the	  authors	  noted,	  
the	   same	   result	   was	   not	   achieved	   by	   using	   the	   reduced	   amide	   isostere	   [87],	  
which	   is	   also	   positively	   charged.	   This	   observation	   suggests	   an	   additional	  
beneficial	  conformational	  effect	  of	  the	  amidine	  isostere,	  which	  is	  more	  rigid	  than	  
the	  reduced	  amide	  isostere.	  	  
	  
In	   contrast	   to	   the	   introduction	   of	   an	   amidine	   isostere	   in	   the	   D-­‐Tyr5-­‐Arg1	  
fragment,	   modification	   of	   this	   amide	   bond	   through	   N-­‐alkylation	   has	   proven	  
fruitful.	   Ueda	   et	   al.	   reported	   the	   N-­‐Me-­‐D-­‐Arg1	   analog	   FC122,	   which	   showed	  
increased	   affinity	   compared	   to	   FC131	   (IC50-­‐values	   of	   3	   and	   4	   nM,	   respectively	  
[89];	   Inokuchi	   et	   al.	   have	   later	   reported	  values	  of	  37	  and	  126	  nM,	   respectively	  
[95]).	   N-­‐methylation	   of	   the	   other	   four	   amide	   bonds	   resulted	   in	   significantly	  
reduced	   activity	   [89],	   i.e.	   a	   completely	   opposite	   trend	   than	   observed	   for	   the	  
corresponding	   amidine	   isosteres	   [95],	   as	   discussed	   above.	   Collectively,	   this	  
shows	   that	   the	   carbonyl	  oxygen	   in	   the	  D-­‐Tyr5-­‐Arg1	   amide	  bond	  plays	  a	   special	  
role,	   while	   the	   amide	   NH	   is	   not	   needed	   for	   activity.	   The	   beneficial	   effect	   of	  
replacing	   L-­‐Arg1	   with	   N-­‐Me-­‐D-­‐Arg1	   was	   attributed	   to	   conformational	  
stabilization	   of	   the	   amide	   bond,	   and	   NMR	   studies	   confirmed	   that	   FC131	   and	  
FC122	  display	  similar	  backbone	  conformations	  [89].	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This	  concept	  was	  further	  developed	  by	  Demmer	  et	  al.	  who	  created	  a	  peptoid-­‐like	  
structure	  by	  replacing	  Arg1	  with	  D-­‐Ala1	  and	  moving	  the	  side	  chain	  to	  the	  amide	  
nitrogen	   [91].	   Fine-­‐tuning	   of	   the	   N-­‐alkyl	   chain	   length	   and	   variation	   of	   the	  
positively	  charged	  functional	  group	  (amine	  or	  guanidine)	  resulted	  in	  the	  highly	  
active	  analog	  1	   (Figure	  5D)	  with	  an	   IC50-­‐value	  of	  0.04	  nM.	  Again,	   the	   increased	  
activity	  was	   explained	   by	   conformational	   effects,	   as	   NMR	   studies	   showed	   that	  
the	   structural	   modifications	   effectively	   “freeze”	   the	   backbone	   in	   the	   bioactive	  
conformation.	  
	  
The	   remaining	   backbone	  modifications	   listed	   above	   have	   generally	   resulted	   in	  
reduced	   activity.	   Even	   if	   designed	   to	   resemble	   an	   amide	  bond,	   an	   isostere	  will	  
have	   different	   structural	   and	   electronic	   properties,	   e.g.	   geometrical,	   steric,	  
conformational,	   and	  H-­‐bond	  donor/acceptor	   properties.	   It	   is	   therefore	  difficult	  
to	  determine	  the	  exact	  reason	  for	  the	  reduced	  activity	  of	  these	  modified	  analogs.	  
	  
4.1.3. Side	  chain	  modifications	  
With	  respect	  to	  the	  relative	  importance	  of	  the	  side	  chains	  for	  activity,	  an	  alanine	  
scan	  of	  FC131	  and	   the	  D-­‐Arg1	  epimer	  FC092	   [89]	   showed	   that	  Arg2	  and	  2-­‐Nal3	  
were	   more	   important	   than	   L-­‐/D-­‐Arg1	   and	   D-­‐Tyr5.	   Extensive	   SAR	   studies	   of	  
FC131	   involving	   more	   conservative	   side	   chain	   modifications	   have	   been	  
performed,	  and	  due	  to	  the	  large	  number	  of	  analogs,	  we	  only	  summarize	  the	  main	  
findings.	  
§ Arg1	  is	  relatively	  tolerant	  to	  a	  range	  of	  structural	  modifications,	  indicating	  that	  
it	  participates	  in	  non-­‐specific	  receptor	  interactions	  [88,	  96,	  97].	  
§ Arg2	  is	  very	  sensitive	  to	  the	  same	  modifications,	  indicating	  that	  it	  is	  involved	  in	  
highly	  specific	  receptor	  interactions	  [97,	  98].	  
§ 2-­‐Nal3	   is	  also	  sensitive	  to	  modifications,	  and	  the	  distal	  aromatic	  ring	  has	  been	  
shown	  to	  be	  especially	  important	  [98,	  99].	  
§ Gly4	   was	   originally	   introduced	   as	   a	   spacer	   for	   synthetic	   feasibility;	   however,	  
replacement	   of	   Gly	   with	   other	   small	   non-­‐polar	   residues	   was	   later	   shown	   to	  
result	  in	  reduced	  activity	  [89].	  
§ D-­‐Tyr5	  remains	  the	  best	  of	  the	  investigated	  phenyl-­‐substituted	  analogs:	  4-­‐OH	  >	  
H	  >	  2-­‐F	  >	  3-­‐F	  >	  4-­‐NH2	  >	  4-­‐F	  >	  4-­‐OMe	  >	  4-­‐Cl	  >	  4-­‐Br	  [96,	  98-­‐100].	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The	  collective	  SAR	  data	  for	  the	  cyclopentapeptide	  CXCR4	  antagonists	  indicate	  a	  
“sidedness”	  in	  the	  molecule,	  where	  one	  half	  (Arg2-­‐2-­‐Nal3)	  provides	  the	  strongest,	  
most	  specific	  interactions	  with	  the	  receptor,	  and	  the	  other	  half	  (D-­‐Tyr5-­‐Arg1)	  less	  
specific,	  but	  still	  beneficial,	  interactions.	  	  
	  
4.1.4. Global	  modifications	  
Also,	  introduction	  of	  larger	  structural	  changes	  while	  keeping	  the	  four	  side	  chain	  
functionalities	   of	   the	   cyclopentapeptide	   ligands	   –	   here	   referred	   to	   as	   global	  
modifications	   –	   has	   been	   attempted.	   Tamamura	   et	   al.	   reported	   two	   different	  
classes	  of	  bridged	  cyclic	  peptides	  that	  were	  designed	  to	  mimic	  FC131	  (Figure	  5E)	  
[88].	  These	  compounds	  are	  essentially	  tetrapeptides	  based	  on	  an	  R1-­‐Xaa1-­‐Arg2-­‐2-­‐
Nal3-­‐Xaa4-­‐R2	   motif,	   where	   R1	   and	   R2	   contain	   the	   two	   other	   pharmacophoric	  
groups	   (positively	   charged	   group	   and	   phenol	   group).	   Cyclization	   between	   the	  
Xaa1	   and	   Xaa4	   side	   chains,	   either	   via	   a	   disulfide	   bridge	   or	   an	   olefin	   bridge,	  
provides	  the	  cyclic	  constraint.	  However,	  in	  both	  cases,	  the	  activity	  was	  generally	  
low,	   the	  most	   active	   compound	   being	   a	   disulfide-­‐bridged	   analog	  with	   an	   IC50-­‐
value	  of	  0.54	  μM,	  which	  was	  approximately	  130-­‐fold	  lower	  than	  for	  FC131.	  Also,	  
the	   absence	   or	   presence	   of	   a	   tyramine	   (R2)	   did	   not	   significantly	   affect	   the	  
activity.	   Collectively,	   the	   findings	   suggest	   a	   suboptimal	   orientation	   of	   the	   four	  
side	  chains	  compared	   to	   the	  parent	  cyclopentapeptides,	  probably	  as	  a	  result	  of	  
the	  relatively	  extensive	  shuffling	  of	  functional	  groups	  in	  the	  R1-­‐Xaa1	  and	  Xaa4-­‐R2	  
fragments.	  
	  
4.1.5. Pharmacophore	  Model	  
Based	   on	   an	   extensive	   exploration	   of	   the	   conformational	   space	   for	   a	   series	   of	  
reported	   cyclopentapeptide	   CXCR4	   antagonists,	   Våbenø	   et	   al.	   have	   proposed	   a	  
minimalistic	   3D	   pharmacophore	   model	   for	   this	   compound	   class	   [101].	   The	  
identified	  features	  included	  the	  spatial	  arrangement	  of	  the	  pharmacophoric	  side	  
chains	  as	  well	  as	   the	  optimal	  conformation	  of	   the	  cyclopentapeptide	  backbone,	  
which	  was	  consistent	  with	  the	  experimental	  solution	  structure	  for	  FC131	  [49].	  	  
	  
4.1.6. Binding	  Mode	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Several	   computational	   models	   of	   the	   complex	   between	   CXCR4	   and	   the	  
cyclopentapeptide	   antagonist	   FC131	   have	   been	   reported	   [99,	   102,	   103],	   and	  
despite	  coming	  from	  three	  different	  groups,	   the	  suggested	  binding	  modes	  were	  
quite	  consistent.	  Importantly,	  none	  of	  these	  studies	  were	  accompanied	  by	  in	  vitro	  
experiments	  that	  verified	  the	  proposed	  binding	  mode.	  However,	  a	  recent	  binding	  
mode	   study	   of	   FC131	   based	   on	   extensive	   site-­‐directed	   mutagenesis	   [104]	  
supports	   the	   previously	   suggested	   binding	  models.	   The	   collective	   picture	   that	  
has	   emerged	   from	   these	  models	   is	   generally	   consistent	   with	   SAR	   (see	   section	  
4.1.3)	   and	   suggests	   a	   critical	   interaction	   between	   Arg2	   of	   FC131	   and	   His113	  
(TM3)	  and	  Asp171	  (TM4).	  Thus,	  the	  essential	  Arg2	  residue	  of	  FC131	  appears	  to	  
have	   the	  same	  binding	  role	  as	  Arg2	  of	  CVX15	  (Figure	  2B)	  and	  Arg	   in	   the	  GPGR	  
motif	  of	  the	  HIV	  V3	  loop	  (Figures	  4B	  and	  C).	  
	  
4.2. Small-­‐Molecule	  Peptidomimetics	  Derived	  from	  FC131	  
	  
4.2.1. Linear	  Peptidomimetics	  
Tamamura	  et	  al.	  have	  performed	  extensive	  SAR	  studies	  on	  tri-­‐	  and	  tetrapeptide	  
mimetics	  starting	  from	  an	  Arg-­‐Arg	  dipeptide	  (Figure	  6A)	  [105].	  The	  C-­‐terminus	  
was	  modified	  by	  addition	  of	  a	  1-­‐(1-­‐napthyl)ethylamine	  group,	  which	  presumably	  
mimics	  the	  naphthalene	  groups	   found	  in	  both	  T140	  and	  FC131,	  and	  also	   in	  the	  
independently	   developed	   KRH-­‐1636	   [106]	   (see	   section	   4.3.1	   and	   Figure	   8A	  
below).	  They	  found	  that	  analogs	  2	  and	  3,	  where	  either	  of	  the	  amide	  bonds	  was	  
replaced	   with	   a	   reduced	   amide	   isostere,	   displayed	   increased	   anti-­‐HIV	   activity	  
albeit	   similar	   inhibition	  of	   [125I]-­‐CXCL12	  binding	   to	  CXCR4	   [105].	   Further,	   they	  
found	   that	   addition	   of	   an	   N-­‐terminal	   Tyr	   residue,	   inspired	   by	   FC131,	   or	  
particularly	   addition	   of	   a	   4-­‐fluorobenzoyl	   group,	   which	   had	   earlier	   been	  
described	  as	  a	  beneficial	  N-­‐terminal	  modification	  for	  T140	  [107],	  increased	  anti-­‐
HIV	   activity	   and	   for	   some	   analogs	   also	   antagonistic	   activity	   against	   CXCR4.	   A	  
series	  of	  N-­‐terminally	  modified	  Arg-­‐Arg-­‐Nal-­‐NH2	  and	  Arg-­‐Nal-­‐NH2	  peptides	  (e.g.	  
4	  and	  5)	  were	  also	  evaluated	  for	  anti-­‐HIV	  and	  CXCR4	  antagonistic	  activity.	  For	  a	  
number	  of	  the	  analogs	  prepared,	  no	  significant	  CXCR4	  binding	  affinity	  could	  be	  
observed	  at	  1	  µM,	  however	   significant	   anti-­‐HIV	  activity	  was	   found	   for	  6	   and	  7	  
(Figure	  6A).	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Figure	  6.	  Structures	  of	  linear	  peptidomimetics	  reported	  by	  (A)	  Tamamura	  et	  al.	  [105],	  and	  (B)	  
Narumi	  et	  al.	  [108].	  See	  Figure	  8A	  for	  the	  structure	  of	  KRH-­‐1636.	  
	  
Compounds	   containing	   two	   Arg	   side	   chains	   were	   generally	   found	   to	   display	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Interestingly,	   as	   the	   authors	   note,	   the	   optimal	   stereochemistry	   of	   the	   1-­‐(1-­‐
napthyl)ethylamide	  was	   found	  to	  differ	   for	   this	  compounds	  series	  compared	  to	  
that	  of	  KRH-­‐1636	  (see	  Figure	  8A).	  The	  differences	  between	  anti-­‐HIV	  potency	  and	  
affinity	  for	  CXCR4	  seen	  throughout	  the	  series	  of	  compounds	  are	  explained	  by	  the	  
differences	  found	  in	  the	  interaction	  of	  HIV	  and	  CXCL12	  with	  the	  receptor.	  None	  
of	   the	  compounds	  showed	  similarly	  high	  anti-­‐HIV	  potency	  or	  CXCR4	   inhibitory	  
activity	  as	  FC131	  or	  T140.	  
	  
In	  a	  later	  SAR	  study	  by	  Narumi	  et	  al.,	  compounds	  with	  only	  one	  Arg	  residue,	  i.e.	  
analogs	   of	   KRH-­‐1636	   and	   7,	   were	   further	   modified	   [108].	   Here,	   the	  
stereochemistry	   of	   the	   1-­‐(1-­‐napthyl)ethylamide	   at	   the	   C-­‐terminus	   was	   varied	  
and	   different	   4-­‐fluorophenyl	   containing	   and	   2-­‐,	   3-­‐	   or	   4-­‐pyridyl	   containing	  
substituents	  were	   introduced	  at	   the	  benzylic	  N-­‐position	   (8-­‐12,	   Figure	  6B).	  The	  
inhibitory	  activity	  against	  CXCR4	  was	  also	  compared	  to	  that	  of	  KRH-­‐1636,	  FC131	  
and	   T140,	   and	   while	   none	   of	   the	   analogs	   displayed	   the	   same	   high	   anti-­‐HIV	  
activity	   or	   CXCR4	   inhibitory	   activity,	   several	   interesting	   observations	   were	  
made.	  As	  for	  earlier	  analogs	  (vide	  supra),	  it	  was	  found	  that	  these	  low	  molecular	  
weight	  compounds	  show	  two	  types	  of	  recognition	  modes	  for	  CXCR4.	  Compounds	  
8,	  9	  and	  10	   	  were	  found	  to	  have	  highest	  anti-­‐HIV	  activity,	  whereas	  compounds	  
11	   and	   12	   displayed	   lower	   anti-­‐HIV	   activity	   but	   similar	   or	   higher	   CXCR4	  
inhibition.	  
	  
4.2.2. Scaffold-­‐Based	  Peptidomimetics	  
The	   successful	   downsizing	   of	   the	   polypeptide	   CXCR4	   antagonists	   to	   the	  
cyclopentapeptide	   FC131	   has	   spurred	   further	   efforts	   toward	   development	   of	  
antagonists	  based	  on	  various	  scaffolds	  onto	  which	  the	  peptide	  pharmacophoric	  
groups	  can	  be	  grafted.	  	  
	  
Tetrapeptidomimetics.	   Cluzeau	   et	   al.	   have	   reported	   a	   series	   of	  
tetrapeptidomimetics	   based	   on	   a	   1,2,5,7-­‐tetrasubstituted	   (E)-­‐1,4,7-­‐
triazacycloundec-­‐9-­‐en-­‐3-­‐one	   scaffold	   (Figure	   7A)	   [109].	   These	   structures	  were	  
designed	   to	   mimic	   FC131;	   however,	   the	   most	   active	   compound	   had	   800-­‐fold	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reduced	   activity	   compared	   to	   FC131	   (IC50-­‐values	   of	   3.2	   and	   0.004	   μM,	  
respectively).	  No	  further	  studies	  on	  this	  compound	  class	  have	  been	  reported.	  
	  
	  
Figure	  7.	  Structures	  of	  reported	  scaffold-­‐based	  (type	  III)	  peptidomimetics.	  
	  
Tripeptidomimetics.	   Marshall	   suggested	   early	   on	   that	   benzodiazepine	   and	  
naphthyldiazepine	  structures	  (13	  and	  14,	  Figure	  7B)	  could	  function	  as	  suitable	  
scaffolds	   for	   Arg-­‐Arg-­‐Nal	   tripeptidomimetics	   [110],	   however,	   details	   regarding	  
biological	  activity	  are	  not	  available.	  	  



















































































































E. 3,6,8-Trisubstituted 6,6-fused bicyclic scaffold
	   33	  
	  
Niida	  and	  co-­‐workers	  have	  showed	  that	  the	  Arg-­‐Arg-­‐Nal	  motif	  of	  FC131	  could	  be	  
grafted	  onto	  a	  3,6-­‐dihydropyridin-­‐2-­‐on	  scaffold,	  which	  was	  intended	  as	  a	  highly	  
functionalized	   diketopiperazine	  mimic,	   to	   give	   a	   low	  molecular	   weight	   CXCR4	  
antagonist	  15	   (Figure	  7C)	   [111].	  No	   further	   investigation	   into	   this	   scaffold	  has	  
been	  published	  to	  date.	  
	  
Ueda	   et	   al.	   have	   reported	   a	   series	   of	   1,2,5-­‐trisubstituted	   indole	   derivatives	  
(Figure	  7D),	  where	  each	  of	   the	   three	  substituents	  was	   introduced	  as	  mimics	  of	  
the	   Arg1-­‐Arg2-­‐Nal3	   or	   Arg2-­‐Nal3-­‐D-­‐Tyr5	   side	   chains	   of	   FC131	   and	   derivatives	  
[112].	   The	   indole	   was	   chosen	   as	   scaffold	   in	   a	   ligand-­‐based	   design	   approach,	  
where	   low	   energy	   conformations	   of	   FC131	   and	  5-­‐acetamido-­‐1-­‐methylindole-­‐2-­‐
carboxamide	  were	  compared.	  The	  distances	  between	  the	  N-­‐atoms	  of	   the	  amide	  
substituents	  and	  the	  methyl	  group	  of	   the	   indole	  derivative	  was	   found	  to	  match	  
well	  with	  the	  distances	  between	  the	  three	  β-­‐carbon	  atoms	  of	  the	  important	  side	  
chains.	   The	   choice	   of	   the	   indole	   scaffold	   offers	   a	   modular	   approach	   to	   the	  
synthesis	   of	   derivates,	   and	   the	  most	   active	   derivative	  16,	   which	   contains	   two	  
guanidine	  groups	  and	  an	  indole	  side	  chains,	  displayed	  an	  IC50	  of	  1.2	  µM.	  This	  is	  
still	  150-­‐fold	  less	  active	  than	  FC131,	  and	  was	  proposed	  by	  the	  authors	  to	  serve	  as	  
a	  useful	  lead.	  
	  
Zachariassen	   et	   al.	   have	   recently	   reported	   on	   the	   synthesis	   of	   scaffold-­‐based	  
tripeptidomimetic	  CXCR4	  antagonists	   [113],	  which	  were	  designed	  to	  mimic	  the	  
Arg1-­‐Arg2-­‐2-­‐Nal3	   motif	   of	   the	   cyclopentapeptides	   discussed	   above.	   After	  
comparison	   of	   the	   proposed	   bioactive	   backbone	   conformation	   of	  
cyclopentapeptide	   CXCR4	   antagonists	   with	   low-­‐energy	   conformations	   of	   the	  
3,6,8-­‐trisubstituted	   bicyclic	   scaffold	   A,	   CXCR4	   antagonists	   based	   on	   A	   and	   its	  
diastereoisomer	   B	   (Figure	   7E)	   were	   pursued.	   While	   bicyclic	   compounds	  
containing	   an	   amide	   bond	   in	   the	   Arg1	   side	   chain	   (17	   and	   its	   diastereoisomer	  
based	   on	   scaffold	   A,	   Figure	   7E)	   showed	   no	   activity	   within	   the	   concentration	  
range	   tested,	   the	   two	   analogs	  with	   an	   unmodified	   Arg1	   side	   chain	   (18	   and	   its	  
diastereoisomer	  based	  on	  scaffold	  B,	  Figure	  7E)	  showed	  antagonistic	  activity	  in	  
the	   micromolar	   range	   in	   a	   cell	   based	   functional	   assay	   for	   CXCR4.	   Thus,	   the	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bicyclic	  scaffolds	  provide	  an	  interesting	  new	  starting	  point	  for	  CXCR4	  antagonist	  
design.	  
	  
4.3. Small-­‐Molecule	   Peptides	   and	   Peptidomimetics	   not	   Derived	   from	  
FC131	  
	  
4.3.1. KRH-­‐series	  	  
In	   2003,	   Ichiyama	   and	   co-­‐workers	   reported	   KRH-­‐1636	   (Figure	   8A)	   as	   a	   non-­‐
peptide	   CXCR4	   antagonist	   with	   highly	   potent	   and	   selective	   anti-­‐HIV-­‐1	   activity	  
[106].	  Structural	  comparison	  of	  low-­‐energy	  conformations	  of	  KRH-­‐1636	  with	  the	  
3D-­‐pharmacophore	   model	   for	   cyclopentapeptide	   antagonists	   later	   suggested	  
that	   the	   (pyridin-­‐2-­‐ylmethyl)amino,	   guanidine	   and	   naphthyl	   groups	   of	   KRH-­‐
1636	  could	  mimic	  the	  Arg1-­‐Arg2-­‐2-­‐Nal3	  fragment	  of	  FC131	  and	  KRH-­‐1636	  is	  thus	  
considered	   as	   a	   tripeptidomimetic	   [101].	   In	   the	   original	   study,	   KRH-­‐1636	  was	  
found	   to	   be	   duodenally	   absorbable	   and	   was	   considered	   as	   a	   promising	   lead.	  
However	  at	  a	   later	  stage	   further	  progression	  of	   this	  compound	  was	  abandoned	  
due	  to	  low	  oral	  bioavailability	  [114].	  	  
	  
After	  the	  initial	  disclosure	  of	  KRH-­‐1636,	  further	  development	  of	  several	  analogs	  
has	   been	   reported,	   e.g.	   KRH-­‐2731	   and	   KRH-­‐3148	   [115],	   but	   the	   literature	   is	  
unclear	  regarding	  the	  structure	  of	  several	  of	   these.	  Examples	  of	  structures	  that	  
have	  been	  assumed	  as	  lead	  structures	  (19	  and	  20)	  are	  shown	  in	  Figure	  8A	  [116].	  
Eventually	  KRH-­‐3955	  (Figure	  8A),	  which	  does	  not	  contain	  any	  amino	  acids,	  was	  
reported	   to	   be	   an	   orally	   bioavailable	   highly	   potent	   inhibitor	   of	   X4	   HIV-­‐1	  
replication	  and	  CXCL12	  mediated	  chemotaxis	  [114,	  115].	  Thus,	  the	  KRH-­‐series	  of	  
compounds	  have	  moved	   from	   initial	  peptide-­‐like	   leads	   into	  a	  more	  cyclam-­‐like	  
clinical	  candidate.	  
	  
4.3.2. Ar-­‐Ar-­‐X	  and	  X-­‐Ar-­‐Ar	  peptides	  	  
Recently,	  Portella	  et	  al.	  reported	  an	  array	  of	  short	  cyclic	  peptides	  containing	  Ar-­‐
Ar-­‐Arg	  or	  Arg-­‐Ar-­‐Ar	  motifs	  as	  a	  novel	  class	  of	  CXCR4	  antagonists,	  and	  several	  of	  
these	   (Figure	   8B)	  were	   found	   to	   inhibit	   growth	   of	   cancer	   cells	   and	   reduce	   the	  
number	  of	  metastases	  in	  mice	  [117].	  The	  peptide	  library	  was	  designed	  based	  on	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the	  identification	  of	  two	  similar	  tripeptide	  motifs	  (although	  in	  reversed	  order)	  in	  
the	  N-­‐terminal	  tail	  of	  vMIP-­‐II	  (Trp5-­‐His6-­‐Arg7)[64]	  and	  in	  the	  N-­‐loop	  of	  CXCL12	  
(Arg12-­‐Phe13-­‐Phe14).	   Cys	   residues	  were	   added	   at	   either	   end	   of	   these	   tripeptide	  
motifs	   and	   the	   structures	  were	   cyclized	   through	   disulfide	   formation.	   Based	   on	  
modeling	   studies,	   the	   details	   of	   which	  were	   not	   revealed,	   the	   authors	   suggest	  
that	   these	   peptides	   bind	   to	   the	   intrahelical	   site	   of	   CXCR4.	  With	   respect	   to	   the	  
original	  design	  concept,	  the	  experimental	  vMIP-­‐II:CXCR4	  structure	  (section	  3.1)	  
now	  provides	  the	  details	  of	  the	  interaction	  between	  the	  Trp5-­‐His6-­‐Arg7	  motif	  and	  
CXCR4,	   while	   the	   proposed	   CXCL12:CXCR4	   complexes	   (section	   3.2)	   describe	  
plausible	   orientations	   of	   the	   Arg12-­‐Phe13-­‐Phe14	   motif.	   However,	   there	   is	   no	  
apparent	  overlap	  between	  these	  two	  motifs.	  
	  
	  
Figure	  8.	  Linear	  peptidomimetics	  and	  side	  chain	  cyclized	  peptides.	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5. FUTURE	  PERSPECTIVE	  	  
	  
The	   literature	  on	  CXCR4	   is	   rapidly	   expanding,	   defining	  new	   roles	  of	  CXCR4,	   or	  
deciphering	  older	  roles	  in	  more	  molecular	  details,	  in	  particular	  within	  cancer	  cell	  
migration,	  i.e.	  metastasis	  [118,	  119].	  
	  
Even	   if	   X-­‐ray	   structures	   of	   CXCR4	   have	   been	   available	   since	   2010,	   the	   major	  
classes	   of	   small-­‐molecule	   peptide/peptidomimetic	   CXCR4	   antagonists	   reported	  
to	  date	  (section	  4)	  have	  been	  developed	  without	  knowledge/consideration	  of	  the	  
CXCR4	  structure,	  i.e.	  by	  ligand-­‐based	  design.	  	  
	  
The	   experimental	   CXV15:CXCR4	   [5]	   and	   vMIP-­‐II:CXCR4	   [6]	   complexes	   (section	  
3.1)	  obviously	  serve	  as	  structural	  templates	  for	  rational	  design	  of	  small-­‐molecule	  
peptidomimetics,	   and	   have	   not	   yet	   been	   properly	   exploited	   for	   this	   purpose.	  
Similarly,	   based	   on	   the	   extensive	   studies	   of	   the	   binding	   mode	   for	   the	  
cyclopentapeptide	  FC131,	  the	  proposed	  FC131:CXCR4	  complex	  [104]	  should	  be	  a	  
viable	   foundation	   for	   structure-­‐based	   downsizing	   and	   optimization	   of	  
peptidomimetic	   ligands.	   Also,	   our	   understanding	   of	   the	  molecular	   interactions	  
between	  CXCR4	  and	  the	  HIV-­‐1	  V3	  loop	  has	  now	  matured	  to	  the	  point	  where	  the	  
recently	   suggested	   computational	  V3:CXCR4	   complexes	   (section	  3.3)	   represent	  
viable	  starting	  points	  for	  rational	  design	  of	  peptidomimetics	  based	  on	  short	  V3-­‐
motifs.	  
	  
The	  continued	  studies	  of	   the	   interactions	  between	  CXCL12	  and	  CXCR4	  (section	  
3.2)	  will	  also	  feed	  important	  insight	  into	  antagonist	  design,	  however;	  so	  far	  the	  
lack	  of	  experimental	  data	  poses	  as	  a	  challenge	   for	   the	  rational	  design	  of	   small-­‐
molecule	   peptidomimetic	   ligands.	   However,	   based	   on	   their	   model	   of	   the	  
CXCL12:CXCR4	   complex,	   Costantini	   [78]	   identified	   Ac-­‐SLSYRC-­‐NH2	   and	   Ac-­‐
YRCPCRF-­‐NH2	   (corresponding	   to	  N-­‐terminal	   residues	   4-­‐9	   and	   7-­‐13	   of	   CXCL12,	  
respectively)	  as	  short	  peptides	  able	  to	  bind	  to	  CXCR4	  with	  promising	  affinity.	  
	  
The	  non-­‐liganded	  X-­‐ray	  structures	  of	  CXCR4	  can	  also	  be	  used	  to	  identify	  new	  hit	  
compounds	  by	  virtual	  screening;	  the	  structural	  nature	  of	  such	  hits	  will	  of	  course	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depend	   on	   the	   (virtual)	   compound	   library	   that	   is	   screened.	   For	   example,	  
Mysinger	   et	   al.	   reported	   the	   identification	   of	   four	   novel	   small-­‐molecule	   CXCR4	  
antagonists	  by	  virtual	  screening	  of	  4.2	  million	  molecules	  from	  the	  ZINC	  database	  
[120];	  however,	  none	  of	  these	  bear	  any	  structural	  resemblance	  to	  known	  peptide	  
ligands	  and	  must	  be	  considered	  as	  functional	  mimetics.	  Interestingly,	  Vitale	  et	  al.	  
recently	  identified	  the	  natural	  product	  phidianidine	  A	  (Figure	  8C)	  as	  a	  potential	  
ligand	  for	  CXCR4	  by	  employing	  a	  partly	  receptor-­‐based	  pharmacophore	  model	  as	  
well	  as	  virtual	  screening;	  subsequent	  in	  vitro	  studies	  confirmed	  phidianidine	  A	  to	  
be	  a	  CXCR4	  antagonist	  [121].	  Structurally,	  phidianidine	  A	  can	  be	  considered	  as	  a	  
topographical	   Arg-­‐Trp	   dipeptidomimetic	   based	   on	   a	   3,5-­‐disubstituted	   1,2,4-­‐
oxadiazole	   scaffold.	   Molecular	   docking	   studies	   indicated	   that	   the	   cationic	  
(guanidine)	  moiety	  of	  phidianidine	  A	  may	  interact	  with	  Asp97,	  Asp187,	  Asp262	  
or	   Glu288	   while	   the	   hydrophobic	   (bromoindole)	   moiety	   involves	   in	   aromatic	  
interactions	  with	  TM1	  and	  TM2.	  Thus,	  phidianidine	  A	   shows	   similar	   structural	  
features	  and	  binding	   interactions	  as	   the	  peptide	  CXCR4	  antagonists	  FC131	  and	  
T140/CVX15.	   This	   study	   shows	   that	   virtual	   screening	   of	   peptide	   (or	   peptide-­‐
like)	   libraries	   also	   holds	   potential	   for	   identification	   of	   novel	   peptidomimetic	  
CXCR4	  antagonists.	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6. EXECUTIVE	  SUMMARY	  	  
	  
§ The	  established	  role	  of	  the	  peptidergic	  7TM	  chemokine	  receptor	  CXCR4	  in	  e.g.	  
HIV-­‐entry,	  cancer,	  and	  inflammation	  means	  that	  CXCR4	  is	  an	  attractive	  target	  
for	  peptidomimetic	  drugs.	  	  
§ The	  X-­‐ray	  structures	  of	  CXCR4	  have	  provided	  a	  reliable	  structural	  foundation	  
for	   computational	   studies	  of	   the	  molecular	   interactions	  between	  CXCR4	  and	  
its	  endogenous	  agonist	  CXCL12	  as	  well	  as	  the	  HIV	  V3	  loop.	  	  
§ The	   cyclopentapeptide	   CXCR4	   antagonists	   represent	   an	   excellent	   starting	  
point	   for	   rational	   development	   of	   small-­‐molecule	   peptidomimetics,	   and	   the	  
SAR	  and	  binding	  mode	  of	  this	  compound	  class	  have	  been	  extensively	  studied.	  
§ Several	   attempts	   to	   develop	   smaller	   and	   more	   drug-­‐like	   scaffold-­‐based	  
peptidomimetic	   CXCR4	   antagonists	   from	   the	   cyclopentapeptides	   have	   been	  
reported;	  however,	  this	  transition	  has	  proven	  challenging.	  
§ Future	   efforts	   toward	   peptidomimetic	   CXCR4	   antagonist	   will	   benefit	   from	  
integration	   of	   the	   ligand-­‐based	   knowledge	   with	   the	   structural	   information	  
that	   now	   is	   available,	   i.e.	   the	   experimental	   complexes	   between	   CXCR4	   and	  
CVX15	  and	  vMIP-­‐II,	  and	  the	  proposed	  complexes	  between	  CXCR4	  and	  CXCL12,	  
HIV	  V3,	  and	  FC131.	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